

0001493152-24-04310010-Q enVveno Medical Corp 2024103020241030192035192035192035 0 0001493152-24-043100 10-Q 44 20240930 20241031 20241030 enVveno Medical Corp 0001661053 3841 330936180 DE 1231 10-Q 34 001-38325 241411902 70 DOPPLER IRVINE CA 92618 949-261-2900 70 DOPPLER IRVINE CA 92618 Hancock Jaffe Laboratories, Inc. 20151215 10-Q 1 form10-q.htm false Q3 --12-31 0001661053 0001661053 2024-01-01 2024-09-30 0001661053 2024-10-28 0001661053 2024-09-30 0001661053 2023-12-31 0001661053 2024-07-01 2024-09-30 0001661053 2023-07-01 2023-09-30 0001661053 2023-01-01 2023-09-30 0001661053 us-gaap:CommonStockMember 2024-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001661053 us-gaap:RetainedEarningsMember 2024-06-30 0001661053 2024-06-30 0001661053 us-gaap:CommonStockMember 2023-06-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001661053 us-gaap:RetainedEarningsMember 2023-06-30 0001661053 us-gaap:CommonStockMember 2023-12-31 0001661053 us-gaap:CommonStockMember 2022-12-31 0001661053 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001661053 us-gaap:RetainedEarningsMember 2022-12-31 0001661053 2022-12-31 0001661053 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001661053 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001661053 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001661053 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001661053 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001661053 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001661053 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001661053 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001661053 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 iso4217:USD xbrli:shares xbrli:pure A A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 A FORM 10-Q A Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the quarterly period ended September 30, 2024 A OR A A TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 A For the transition period from to A Commission file number: 001-38325 A enVveno Medical Corporation (Exact name of registrant as specified in its charter) A Delaware A 33-0936180 (State or other jurisdiction of incorporation or organization) A (I.R.S. Employer Identification No.) A 70 Doppler Irvine, California 92618 (Address of principal executive offices) A (949) 261-2900 (Registrant's telephone number, including area code) A Securities registered pursuant to Section 12(b) of the Act: A Title of Each Class: A Name of Each Exchange on Which Registered: A Ticker Symbol Common Stock, \$0.00001 par value A The NASDAQ Stock Market LLC A NVNO A Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes A No A A Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (A\$232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes A No A A Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of Acelarge accelerated filer,A accelarated filer,A A smaller reporting company,A and Aemerging growth companyA in Rule 12b-2 of the Exchange Act. A Large accelerated filer A Accelerated filer A Non-accelerated filer A Smaller reporting company A A Emerging growth company A A If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. A A Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). A Yes A No A A As of October 28, 2024, there were 17,536,000 shares of common stock outstanding. A A A A ENVVENO MEDICAL CORPORATION TABLE OF CONTENTS A PART I A A FINANCIAL INFORMATION A 1 A ITEM 1. Financial Statements (Unaudited) 1 A A Condensed Balance Sheets as of September 30, 2024 and December 31, 2023 1 A A Condensed Statements of Operations for the three and nine months ended September 30, 2024 and 2023 2 A A Condensed Statements of Changes in Stockholders' Equity for the nine months ended September 30, 2024 and 2023 3 A A Condensed Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 4 A A Notes to Condensed Financial Statements 5 A A ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 9 A A ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 15 A A ITEM 4. Controls and Procedures 15 A A PART II A A OTHER INFORMATION 16 A A ITEM 1. Legal Proceedings 16 A A ITEM 1A. Risk Factors 16 A A ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 16 A A ITEM 3. Defaults Upon Senior Securities 16 A A ITEM 4. Mine Safety Disclosures 16 A A ITEM 5. Other Information 16 A A ITEM 6. Exhibits 17 A A Signatures 18 A i A A PART I A A FINANCIAL INFORMATION A ITEM 1 A A Financial Statements A ENVVENO MEDICAL CORPORATION CONDENSED BALANCE SHEETS (Unaudited) A A September 30, 2024A A December 31, 2023A (In thousands except par values, unless otherwise indicated) A A A A AssetsA A A A A A Current Assets:A A A A A A Cash and cash equivalentsA \$17,915A A \$3,620A Short-term investmentsA A 30,464A A A 42,792A Prepaid expenses and other current assetsA A 672A A A 511A Total current assetsA A 49,051A A A 46,923A Property and equipment, netA A 218A A A 334A Operating lease right-of-use assets, netA A 1,090A A A 1,347A Security deposits and other assetsA A 31A A A 31A Total assetsA \$50,390A A \$48,635A A A A A Liabilities and Stockholders' EquityA A A A A A Current Liabilities:A A A A A A Accounts payable, accrued expenses and other current liabilitiesA \$1,872A A \$1,033A Current portion of operating lease liabilitiesA A 357A A A 338A Total current liabilitiesA A 2,229A A A 1,371A Long-term operating lease liabilitiesA A 791A A A 1,064A Total liabilitiesA A 3,020A A A 2,435A A A A A Commitments and ContingenciesA A A A A A A A A A Stockholders' Equity:A A A A A A Preferred stock, par value \$0.00001, 10,000 shares authorized: no shares issued or outstandingA A A A A A Common stock, par value \$0.00001, 250,000 shares authorized, 17,536 and 13,317 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectivelyA A A A A A Additional paid-in capitalA A 192,996A A A 176,236A Accumulated deficitA A (145,626)A A (130,036) Total stockholders' equityA A 47,370A A A 46,200A Total liabilities and stockholders' equityA \$50,390A A \$48,635A A See Notes to these Unaudited Condensed Financial Statements A 1 A A ENVVENO MEDICAL CORPORATION CONDENSED STATEMENTS OF OPERATIONS (Unaudited) A A 2024A A 2023A A 2024A A 2023A A A For the Three Months EndedA A For the Nine Months EndedA A A September 30,A A September 30,A A 2024A A 2023A A 2024A A 2023A (In thousands, except per share data) A A A A A A Operating Expenses:A A A A A A A A A A Research and development expensesA A 2,859A A A 2,798A A A 8,736A A A 10,602A Selling, general and administrative expensesA A 3,311A A A 2,551A A A 8,391A A A 8,358A Loss from OperationsA A (6,170)A A A (5,349)A A A (17,127)A A A (18,960) A A A A A A A A Other Income:A A A A A A A A A A Realized gain from sales of trading securitiesA A 428A A A 148A A A 1,215A A A 398A Unrealized gain from trading securitiesA A 6A A A 156A A A 96A A A 567A Interest income, netA A 94A A A 44A A A 226A A A 128A Total Other IncomeA A 528A A A 348A A A 1,537A A A 1,093A Net LossA \$(5,642)A A \$(5,001)A A \$(15,590)A A \$(17,867)A A A A A A A A A A Net Loss Per Basic and Diluted Common Share:A \$(0.35)A A (0.45)A A A (0.97)A A A (1.59)A A A A A A A A A A Weighted Average Number of Common Shares Outstanding:A A A A A A A A A A Basic and DilutedA A 16,067A A A 11,231A A A 16,063A A A 11,231A A See Notes to these Unaudited Condensed Financial Statements A 2 A A ENVVENO MEDICAL CORPORATION CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (In thousands, unless otherwise indicated) (Unaudited) A A SharesA A AmountA A CapitalA A DeficitA A EquityA A Three Months Ended September 30, 2024A A Common StockA A Additional Paid-inA A AccumulatedA A Total Stockholders' A A A SharesA A AmountA A CapitalA A DeficitA A EquityA Balance at July 1, 2024A A 13,330A A A A \$178,402A A A (139,984)A A \$38,418A Common Stock and Warrants Issued in Public OfferingA A 4,206A A A A A 13,591A A A A 13,591A Share-Based CompensationA A A A A A A A 1,003A A A A A 1,003A Net lossA A A A A A A A A A (5,642)A A A (5,642) Balance at September 30, 2024A A 17,536A A A \$-A A \$192,996A A A (145,626)A A \$47,370A A A A SharesA A AmountA A CapitalA A DeficitA A EquityA A Three Months Ended September 30, 2023A A Common StockA A Additional Paid-inA A AccumulatedA A Total Stockholders' A A A SharesA A AmountA A CapitalA A DeficitA A EquityA Balance at July 1, 2023A A 9,472A A A A \$148,198A A A (\$119,386)A A \$28,812A Share-Based CompensationA A A A A A A A 1,104A A A A 1,104A Net lossA A A A A A A A A A (5,001)A A A (5,001) Balance at September 30, 2023A A 9,472A A A \$-A A \$149,302A A A (\$124,387)A A \$24,915A A A SharesA A AmountA A CapitalA A DeficitA A EquityA A Nine Months Ended September 30, 2024A A Common StockA A Additional Paid-inA A AccumulatedA A Total Stockholders' A A A SharesA A AmountA A CapitalA A DeficitA A EquityA Balance at January 1, 2024A A 13,317A A A \$-A A \$176,236A A A (\$130,036)A A \$46,200A Common Stock and Warrants Issued in Public OfferingA A 4,206A A A A A 13,591A A A A 13,591A Share-Based CompensationA A A A A A A A 3,123A A A A 3,123A Options exercisedA A 13A A A A 46A A A A 46A Net lossA A A A A A A A A A (15,590)A A A (15,590) Balance at September 30, 2024A A 17,536A A A \$-A A \$192,996A A A (\$145,626)A A \$47,370A A A A SharesA A AmountA A CapitalA A DeficitA A EquityA A Nine Months Ended September 30, 2023A A Common StockA A Additional Paid-inA A AccumulatedA A Total Stockholders' A A A SharesA A AmountA A CapitalA A DeficitA A EquityA Balance at January 1, 2023A A 9,472A A A \$-A A \$145,249A A A (\$106,520)A A \$38,729A Balance A A 9,472A A A \$-A A \$145,249A A A (\$106,520)A A \$38,729A Share-Based CompensationA A A A A A A A 4,053A A A A 4,053A Net lossA A A A A A A A A A (17,867)A A A (17,867) Balance at September 30, 2023A A 9,472A A A \$-A A \$149,302A A A (\$124,387)A A \$24,915A A A 9,472A A A \$-A A \$149,302A A A See Notes to these Unaudited Condensed Financial Statements A 3 A A ENVVENO MEDICAL CORPORATION CONDENSED STATEMENTS OF CASH FLOWS (In thousands, unless otherwise indicated) (Unaudited) A A 2024A A 2023A A A For the Nine Months EndedA A September 30,A A 2024A A 2023A Cash Flows from Operating ActivitiesA A A A A A Net lossA \$(15,590)A A (\$17,867) Adjustments to reconcile net loss to net cash used in operating activities:A A A A A A Share-based compensationA A 3,123A A A 4,052A Depreciation and amortizationA A 149A A A 165A Amortization of right-of-use assetsA A 257A A A 247A Unrealized gain from investments, netA A (96)A A A (567) Changes in operating assets and liabilities:A A A A A A Prepaid expenses and other current assetsA A (118)A A A (155) Security deposit and other assetsA A (43)A A A (8) Accounts payable, accrued expenses and other current liabilitiesA A 839A A A 484A Operating lease liabilitiesA A (254)A A A (236) Net Cash Used in Operating ActivitiesA A (11,733)A A A (13,885) A A A A A A Cash Flows from Investing ActivitiesA A A A A A Purchase of property and equipmentA A (33)A A A (29) Purchases of investmentsA A (33,420)A A A (24,276) Maturities of investmentsA A 45,844A A A 38,581A Net Cash Provided by Investing ActivitiesA A 12,391A A A 14,276A A A A A A Cash Flows from Financing ActivitiesA A A A A A Proceeds from public offeringA A 13,591A A A A Proceeds from stock option exercisesA A 46A A A A Net Cash Provided by Financing ActivitiesA A 13,637A A A A Net Increase in Cash, Cash EquivalentsA A 14,295A A A 391A Cash, cash equivalents - Beginning of periodA A 3,620A A A 4,555A Cash, cash equivalents - End of periodA \$17,915A A \$4,946A A See Notes to these Unaudited Condensed Financial Statements A 4 A A ENVVENO MEDICAL CORPORATION NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) A Note 1 A A Business Organization and Nature of Operations A enVveno Medical Corporation (the ACompanyA) is a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe Chronic Venous Insufficiency (A CVI A) of the deep venous system of the leg. A The Company's lead product is the VenoValve®, which is a potential first-in-class surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The Company is also developing a second product called enVVe®, which is a potential first-in-class, non-surgical, transcatheter based replacement venous valve system consisting of the enVVe valve, the enVVe delivery system, and the delivery system accessories. The Company is currently conducting pre-clinical testing on enVVe. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. A The VenoValve and enVVe are being developed first for approval by the U.S. Food and Drug Administration (FDA). We expect the VenoValve to be eligible for FDA approval

first, followed two to three years later by enVVe. If approved, we expect the VenoValve and enVVe to co-exist, with the VenoValve as a surgical replacement venous valve option and enVVe as a non-surgical replacement venous valve option. Â Note 2 Â€‘‘ Managementâ€™’s Liquidity Plan Â As of September 30, 2024, the Company had a cash and investment balance of \$48.4 million and working capital of \$47.3 million. Although the Company expects to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain its operations, pursue its product development initiatives and penetrate markets for the sale of its products, management believes that the Companyâ€™’s capital resources are sufficient to meet its obligations as they become due within one year after the date of this Quarterly Report, and sustain operations. Â 5 Â Â ENVVENO MEDICAL CORPORATION NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Â Note 3 Â€‘‘ Significant Accounting Policies Â Basis of Presentation Â The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (â€™œGAAPâ€™œ) for interim financial information and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed financial statements of the Company as of September 30, 2024 and December 31, 2023, and for the three and nine months ended September 30, 2024 and 2023. Â The results of operations for the three and nine months ended September 30, 2024 are not necessarily indicative of the operating results for the full year. These unaudited condensed financial statements should be read in conjunction with the financial statements and notes thereto for the year ended December 31, 2023 included in the Companyâ€™’s Annual Report on Form 10-K filed with the SEC on February 29, 2024. The accompanying condensed balance sheet as of December 31, 2023 has been derived from the Companyâ€™’s audited financial statements. Â Note 4 Â€‘‘ Investments Â The components of investments were as follows at September 30, 2024 and December 31, 2024: Â Schedule of Components of Investments (In thousands) Â Â Â Â September 30, 2024 Â Â Â December 31, 2023 Â Â Â Â Â Â Cash Equivalents Â Â Short-Term Investments Â Â Cash Equivalents Â Â Short-Term Investments Â Fair Value Level 1 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â U.S. Government securities Â \$3,794 Â Â \$30,464 Â Â \$3,187 Â Â \$42,792 Â Total debt investments Â \$3,794 Â Â \$30,464 Â Â \$3,187 Â Â \$42,792 Â Unrealized and realized gains and losses on the accompanying statement of operations result from fixed-income securities and are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on our evaluation of available evidence. Â 6 Â Â ENVVENO MEDICAL CORPORATION NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Â Note 5 Â€‘‘ Concentrations Â The Company maintains cash with major financial institutions. Cash held in United States bank institutions is currently insured by the Federal Deposit Insurance Corporation (â€™œFDICâ€™œ) up to \$250,000 at each institution. There were aggregate uninsured cash balances of \$14.9 million and \$3.4 million as of September 30, 2024 and December 31, 2023, respectively. Â Note 6 Â€‘‘ Accounts Payable, Accrued Expenses and Other Current Liabilities Â As of September 30, 2024, and December 31, 2023, accounts payable, accrued expenses and other current liabilities consist of the following: Â Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities (In thousands) Â September 30, 2024 Â Â December 31, 2023 Â Accounts payable Â \$894 Â Â \$427 Â Accrued compensation costs Â \$446 Â Â \$478 Â Other accrued expenses Â \$532 Â Â \$128 Â Total accrued expenses and other current liabilities Â \$1,872 Â Â \$1,033 Â Note 7 Â€‘‘ Commitments and Contingencies Â Litigations Claims and Assessments Â In the normal course of business, the Company may be involved in legal proceedings, claims and assessments arising in the ordinary course of business. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Â 7 Â Â ENVVENO MEDICAL CORPORATION NOTES TO CONDENSED FINANCIAL STATEMENTS (Unaudited) Â Note 8 Â€‘‘ Stockholdersâ€™’ Equity Â Equity Issuance Â The Company consummated a public offering on September 30, 2024 whereby it raised net proceeds of \$13.3 million and issued 4.2 million shares of common stock, 0.1 million prefunded warrants and 0.3 million warrants to the underwriter. The weighted average exercise price of the warrants is \$3.18. Â A Transaction fees in connection with the capital raise were \$1.4 million. Â The warrants have a fair value of \$1.0 million based on the Black Scholes method and the following weighted average input assumptions: Â Schedule of Estimated Fair values and Assumptions Â Contractual term in years Â Â 5 Â Volatility Â Â 102% Risk free interest rate Â Â 4% Dividend yield Â Â 0% Â Stock Options Â Stock-based compensation is reflected in selling, general and administrative expenses in the accompanying condensed statements of operations and was \$1.0 million and \$1.1 million during the three months ended September 30, 2024 and 2023, respectively, and \$3.1 million and \$4.1 million during the nine months ended September 30, 2024 and 2023. Â As of September 30, 2024, there was \$4.3 million of unrecognized stock-based compensation expense related to outstanding stock options that will be recognized over the weighted average remaining vesting period of 1.9 years. Â Note 9 Â€‘‘ Net Loss per Share Â The following table summarizes the number of potentially dilutive common stock equivalents excluded from the calculation of diluted net loss per common share as of September 30, 2024 and 2023: Â Schedule of Dilutive Net Loss Per Common Share (In thousands) Â 2024 Â Â 2023 Â Â September 30, Â (In thousands) Â 2024 Â Â 2023 Â Shares of common stock issuable upon exercise of warrants Â \$9,847 Â Â \$4,506 Â Shares of common stock issuable upon exercise of options Â \$5,552 Â Â \$4,254 Â Potentially dilutive common stock equivalents excluded from diluted net loss per share Â Â 15,399 Â Â \$8,760 Â Â Â 8 Â Item 2: MANAGEMENTâ€™’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Â The following discussion should be read in conjunction with our unaudited condensed financial statements and notes thereto included herein. In connection with, and because we desire to take advantage of, the â€™œsafe harborâ€™œ provisions of the Private Securities Litigation Reform Act of 1995, we caution readers regarding certain forward-looking statements in the following discussion and elsewhere in this Quarterly Report and in any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results or other developments. Such forward-looking statements involve significant risks and uncertainties. Forward looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. Words such as â€™œanticipate,â€™œ â€™œestimate,â€™œ â€™œplan,â€™œ â€™œcontinue,â€™œ â€™œongoing,â€™œ â€™œexpect,â€™œ â€™œbelieve,â€™œ â€™œintend,â€™œ â€™œmay,â€™œ â€™œwill,â€™œ â€™œshould,â€™œ â€™œcould,â€™œ and similar expressions are used to identify forward-looking statements. Such forward-looking statements also involve other factors which may cause our actual results, performance or achievements to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this Quarterly Report. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Â Unless the context requires otherwise, references in this document to â€™œNVNOâ€™œ, â€™œweâ€™œ, â€™œourâ€™œ, â€™œusâ€™œ or the â€™œCompanyâ€™œ are to enVeno Medical Corporation. Â Overview Â enVeno Medical Corporation is a late clinical-stage medical device company focused on the advancement of innovative bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. Chronic Venous Disease (â€™œCVDâ€™œ) is the worldâ€™’s most prevalent chronic disease, impacting approximately 70% of the adult population of the U.S. Chronic Venous Insufficiency (â€™œCVIâ€™œ), is a large subset of CVD, which most often occurs when valves inside of the veins of the leg become damaged, resulting in the backwards flow of blood (reflux), blood pooling in the lower leg, increased pressure in the veins of the leg (venous hypertension) and in severe cases, venous ulcers that are difficult to heal. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe CVI of the deep venous system of the leg. Â The Companyâ€™’s lead product is the VenoValveâ€™œ, which is a potential first-in-class surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study called the SAVVE trial (Surgical Anti-reflux Venous Valve Endoprosthesis). Definitive one year data from SAVVE is expected to be released in the fourth quarter of 2024. Â The Company is also developing the next generation replacement venous valve called enVVeâ€™œ, which will be delivered via transcatheter as opposed to an open surgery. The Company is conducting pre-clinical testing on enVVe and currently expects to be ready to file for IDE approval for the enVVe pivotal trial in mid 2025. Â Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. Â The VenoValve and enVVe are being developed first for approval by the U.S. Food and Drug Administration (â€™œFDAâ€™œ). We expect to be eligible to file for FDA approval of the VenoValve in the fourth quarter of 2024 followed approximately three years later by enVVe. If approved, we expect the VenoValve and enVVe to co-exist, with the VenoValve as a surgical replacement venous valve option and enVVe as a non-surgical replacement venous valve option, although we cannot provide any assurance that either the VenoValve or enVVe will receive approval from the FDA. There are currently no devices approved as surgical or non-surgical replacement venous valves, and there are currently no effective treatments for deep venous CVI caused by incompetent valves. Â Our team of officers and directors has been affiliated with numerous medical devices that have received FDA approval or CE marking and that have been commercially successful. We develop and manufacture both the VenoValve and enVVe in a 14,000 sq. ft. leased manufacturing facility in Irvine, California, which has been ISO 13485-2016 certified for the design, development and manufacturing of tissue based implantable medical devices. Â 9 Â Â CVI Background Â Chronic venous disease (CVD) is the worldâ€™’s most prevalent chronic disease. CVD is clinically classified using a standardized system known as CEAP (clinical, etiological, anatomical, and pathophysiological). The CEAP system consists of seven clinical classifications (C0 to C6) with C4, C5 and C6 being the most severe categories of CVD. Â Chronic Venous Insufficiency (CVI) is a large subset of CVD and is generally used to describe patients with C4 to C6 CVD. CVI is a debilitating condition that affects the venous system of the leg causing pain, swelling, edema, skin changes, and ulcerations. Â The human leg contains three vein systems: the deep vein system, the superficial vein system, and the perforator vein system which connects the deep system to the superficial system. The deep venous system is located below the muscle and fascia in the center portion of the leg and is responsible for approximately 90% of the blood flow. In order for blood to return to the heart from the foot, ankle, and lower leg, the calf muscle serves as a pump and pushes the blood up the veins of the leg against gravity and through a series of one-way valves. Each valve is supposed to open as blood passes through, and then close as blood progresses up the veins of the leg to the next valve. CVI occurs when the one-way valves in the veins of the leg fail and become incompetent. When the valves fail, gravity causes the blood to flow backwards and in the wrong direction (reflux). As blood pools in the lower leg, pressure inside the veins increases (venous hypertension). Reflux, and the resulting venous hypertension, causes the leg to swell, resulting in debilitating pain, and in the most severe cases, venous ulcers. Â Severe CVI sufferers experience a significantly reduced quality of life. Daily activities such as preparing meals, housework, dressing, and personal hygiene (washing and bathing) become difficult due to reduced mobility. For many severe CVI sufferers, intense pain, which frequently occurs at night, prevents them from getting adequate sleep. Severe CVI sufferers are known to miss approximately 40% more workdays than the average worker. A high percentage of venous ulcer patients also experience severe itching, leg swelling, and an odorous discharge. Wound dressing changes, which occur several times a week, can be extremely painful. Venous ulcers from deep venous CVI are very difficult to heal, and a significant percentage of venous ulcers remain unhealed for more than a year. Even if healed, recurrence rates for venous ulcers are known to be high (20% to 40%) within the first year and as high as 60% after five years. Patients with severe CVI often become housebound and experience social isolation due to difficulty with ambulation. As a result, studies have shown that patients with active venous ulcers experience higher rates of anxiety and depression, with reported rates of anxiety of up to 30% and depression up to 40%. Rates of depression caused by venous ulcers among the elderly are even higher, with 48% of elderly venous ulcer patients having severe depressive symptoms. Â Prevalence is generally defined as the portion of the population that has a given condition. Estimates indicate that the prevalence of people in the U.S. with severe, deep venous CVI (C4 to C6 disease) with reflux to be approximately 20 million. Incidence is generally defined as the number of new cases of an ailment that develop in a given time period. We estimate that approximately 3.5 million new patients with severe deep venous CVI are diagnosed each year in the U.S. including patients that develop venous leg ulcers (C6 patients). The average patient seeking treatment of a venous ulcer spends as much as \$30,000 a year on wound care, and the total direct medical costs from venous ulcer sufferers in the U.S. has been estimated to exceed \$3 billion a year. Â 10 Â Â VenoValve Â The VenoValve is a replacement venous valve developed at enVeno Medical to be surgically implanted in the deep venous system of the leg to treat severe CVI caused by valvular incompetence. By lowering pressure (venous hypertension) within the deep venous system of the leg, the VenoValve has the potential to reduce or eliminate the symptoms of severe deep venous CVI, including the potential to heal recurring venous leg ulcers. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. As our planned initial entrant to the replacement venous valve market, we estimate that approximately 2.5 million people each year with severe deep venous CVI in the U.S. would be candidates for the VenoValve. The VenoValve has been granted Breakthrough Device designation by the FDA. Â VenoValve Clinical Status Â In March of 2021 we received IDE approval from the FDA to begin the VenoValve pivotal study. An investigational device exemption or IDE from the FDA is required before a medical device company can proceed with a pivotal trial for a Class III medical device. This approval allowed us to proceed with our U.S. pivotal study for the VenoValve which is called the SAVVE (Surgical Anti-reflux Venous Valve Endoprosthesis) clinical study. The SAVVE study is a prospective, non-blinded, single arm, multi-center study of seventy-five (75) CVI patients enrolled at 21 U.S. sites. Â Efficacy endpoints for the SAVVE pivotal study include rVCSS scores, which are used to provide evidence of clinically meaningful benefit, as well as reflux time

measurements, VAS pain scores, quality of life measurements, ulcer healing (for CEAP class C6 patients), and intra-operative and one-year vein patency and valve functionality. Safety endpoints include device related events and procedure related events including mortality, pulmonary embolism, ipsilateral deep vein thrombosis, infection and bleeding. We achieved full enrollment of 75 subjects in the SAVVE trial on September 1, 2023, having enrolled eighteen (18) patients over the final two (2) months of the study. On November 16, 2023, we presented preliminary device related thirty-day Device Related Material Adverse Event (dMACE) data at the 50th Annual VEITH Symposium. The preliminary device related MAE rate for the fully enrolled 75 subject study was eight percent (8%). MAEs for the SAVVE study are defined as all-cause mortality, pulmonary embolisms (PEs), ipsilateral deep vein thromboses (DVTs), bleeding, and deep wound infections, occurring within thirty (30) days of enrollment in the study, being either device or procedure related. The device related MAEs presented at the conference indicated no deaths, no pulmonary embolisms, and six (6) DVTs, from the fully enrolled cohort of 75 patients. Subsequent to the VEITH presentation, two (2) of the DVTs were adjudicated by the SAVVE Clinical Events Committee (cCEC) as being moderate and four (4) of the DVTs were adjudicated as being mild. In addition to the DVTs, the safety report also noted a higher-than-expected rate of pocket wound hematomas (anti-coagulation related bleeding outside of the target vein within the surgical cavity) within the first two (2) weeks after surgery, which were deemed to be moderate in severity by the CEC, as well as an expected rate of procedure related wound infections at the site of the skin incisions. The bleeds and wound infections were acute in nature and had no lasting negative impact on patient health or clinical outcomes. On March 6, 2024, we released initial, six-month topline preliminary revised Venous Clinical Severity Score (rVCSS) efficacy data from the SAVVE study at the VENOUS2024 American Venous Forum Annual Meeting, in Tampa Florida. The data released at VENOUS 2024 indicated that, overall, 97% of the study patients receiving the VenoValve showed clinical improvement as measured by rVCSS at six months, compared to baseline, with 74% of the study patients improving the three (3) or more rVCSS points needed to demonstrate VenoValve's clinical meaningful benefit (the Clinical Meaningful Benefit). The average improvement among the Clinical Meaningful Benefit cohort was 8 points, more than two and a half times the amount of rVCSS improvement required to demonstrate that the VenoValve provides Clinical Meaningful Benefit. On April 24, 2024, follow-on preliminary rVCSS data was presented at the 46th Annual Charing Cross Symposium in London, England. At a weighted average subject follow-up of 11.64 months, the average improvement among the Clinical Meaningful Benefit (approximately 3 point rVCSS improvement) patient cohort was 8.46 points, including 9.29 points for patients at the two-year milestone, 8.08 points for patients at the one-year milestone, and 8.71 points for patients at the six-month milestone. All rVCSS evaluations were based on the patient's most recent clinical visit, compared to baseline. Overall, 94% of the study patients receiving the VenoValve showed clinical improvement as measured by rVCSS, at a weighted-average patient follow-up of 11.04 months for the clinical improvement cohort, and 72% of the study patients improved the three or more rVCSS points needed to demonstrate the VenoValve's Clinical Meaningful Benefit, at a weighted-average patient follow-up of 11.64 months for the Clinical Meaningful Benefit cohort. Total patient follow-up was 762 months for the clinical improvement cohort and 582 months for the Clinical Meaningful Benefit cohort. On June 21, 2024, the Company presented data showing significant improvement for patients with venous ulcers enrolled in the SAVVE study at the Society for Vascular Surgery 2024 Vascular Annual Meeting in Chicago. The data presented included twenty-one venous ulcer patients who had reached their one-year milestone, representing thirty venous ulcers. Overall, 91% of venous ulcer patients evaluated at one year either had fully healed ulcers or ulcers that had improved. Of that group, 100% of venous ulcers with a duration of one year or less prior to VenoValve surgery were fully healed, with the majority (67%) fully healed 90 days after VenoValve surgery. For those with venous ulcers with a duration of more than one year prior to VenoValve surgery, 89% were either fully healed or improved at one year, representing a decrease in average of total ulcers of 85%. In addition, none of the patients with a fully healed venous ulcer had experienced an ulcer recurrence. The FDA has indicated that one-year data on all patients will be necessary prior to completing the application seeking pre-market approval (PMA) for the VenoValve. On August 14, 2024, the Company announced it had filed and the FDA had approved four of the required five modules of its PMA application. The Company expects to file the fifth and final module of its PMA application in Q4 of 2024. enVVe On September 21, 2022, we announced the development of a non-surgical transcatheter based replacement venous valve called enVVe®, for the treatment of CVI of the deep veins of the leg. enVVe is designed to be delivered into the femoral vein of the patient via a minimally invasive procedure requiring no general anesthesia and no overnight hospital stay. Due to the minimally invasive nature of the procedure, we expect to be able to reach patients with less severe CVI or who may otherwise be poor candidates for a surgical device, and estimate the U.S. market for enVVe to be approximately 3.5 million patients. On October 28, 2024, we announced the successful start to a six-month pre-clinical GLP study for enVVe. The first wave of implants, for the long-term subjects, was successfully completed, with the final wave for the shorter-term subjects scheduled for December. The GLP study is a prerequisite to seeking IDE approval from the FDA to begin the enVVe U.S. pivotal study. The Company expects to file for IDE approval for the enVVe pivotal study in mid 2025. Capital We finished 2023 with approximately \$46.4 million of cash and investments and had approximately \$48.4 million of cash and investments at September 30, 2024. Our future capital requirements will remain dependent upon a variety of factors, especially including the success of our clinical trials, related product development costs, and our ability to successfully bring products to market. We anticipate that our cash burn rate will increase from current levels of approximately \$4 million to \$5 million per quarter as we conduct our clinical trials and work toward bringing our product candidates to market. On September 30, 2024, we closed a public offering raising approximately \$13.6 million net cash proceeds. Based on management's current expectations, this capital has the potential to fund the Company through several significant milestones, including the anticipated FDA pre-market approval of the VenoValve, the beginning of preparations for VenoValve commercialization, and the initial stages of the pivotal trial for enVVe. Although we expect our quarterly cash burn rate will increase over time to support these milestones, after the additional proceeds from our offering, we believe we have sufficient cash to fund operations past what we expect will be regulatory approval of the VenoValve and the start of the enVVe pivotal trial. 12 A Comparison of the three months ended September 30, 2024 and 2023 Overview We reported net losses of \$5.6 million and \$5.0 million for the three months ended September 30, 2024 and 2023, respectively, representing an increase in net loss of \$0.6 million or 12%, due to an increase in operating expenses of \$0.8 million, and an increase in other income of \$0.2 million. Revenues As a developmental stage Company, we are not currently generating revenue and our future revenue, if any, is expected to be diminutive in the near future and dependent on our ability to commercialize our product candidates. A Research and Development Expenses For the three months ended September 30, 2024, research and development expenses increased by \$0.1 million or 2%, to \$2.9 million from \$2.8 million for the three months ended September 30, 2023. This increase primarily resulted from \$0.2 million in increased personnel costs to support the SAVVE study and enVVe development, partially offset by a \$0.1 million decrease in lab costs. A Selling, General and Administrative Expenses For the three months ended September 30, 2024, selling, general and administrative expenses increased by \$0.7 million or 27%, to \$3.3 million from \$2.6 million for the three months ended September 30, 2023. This increase was due to a \$0.2 million increase in consulting expense related to market research for the Company's products, and a \$0.7 million increase in legal costs, partially offset by a \$0.1 million decrease in share-based compensation, and a \$0.1 million decrease in travel expenses due to full enrollment of the SAVVE study during 2023 resulting in less travel to study sites in 2024. A Other Income For the three months ended September 30, 2024, other income increased \$0.2 million or 52.0% to \$0.5 million from \$0.3 million for the three months ended September 30, 2023. Other income in both periods reflects realized gains, interest, and unrealized gains from our program to invest excess cash in US Treasury bills. A Comparison of the nine months ended September 30, 2024 and 2023 Overview We reported net losses of \$15.6 million and \$17.9 million for the nine months ended September 30, 2024 and 2023, respectively, representing a decrease in net loss of \$2.3 million, or 13%, due to a decrease in operating expenses of \$1.8 million, and an increase in other income of \$0.4 million. Revenues As a developmental stage Company, we are not currently generating revenue and our future revenue, if any, is expected to be diminutive in the near future and dependent on our ability to commercialize our product candidates. A 13 A Research and Development Expenses For the nine months ended September 30, 2024, research and development expenses decreased by \$1.9 million or 18%, to \$8.7 million from \$10.6 million for the nine months ended September 30, 2023. A This decrease resulted from a \$2.7 million reduction in costs related the SAVVE study as it reached full enrollment during the 2023 period requiring less study related enrollment activity during the 2024 period, partially offset by \$0.8 million higher compensation cost due to increases in staffing. A Selling, General and Administrative Expenses For the nine months ended September 30, 2024, selling, general and administrative expenses of \$8.4 million were flat when compared to the nine months ended September 30, 2023. This is due to \$1.0 million in lower share-based compensation from the reduction in expense from grants made during 2021, the cost for portions of which have been fully recognized, a \$0.1 million decrease in travel expenses due to full enrollment of the SAVVE study during 2023 resulting in less travel to study sites in 2024, partially offset by \$0.8 million in higher legal cost and a \$0.3 million increase in consulting expense related to market research for the Company's products. A Other Income For the nine months ended September 30, 2024, other income increased \$0.4 million to \$1.5 million from \$1.1 million for the nine months ended September 30, 2023. Other income in both periods reflects realized gains, interest, and unrealized gains from our program to invest excess cash in U.S. bills. A Liquidity and Capital Resources For the nine-months ended September 30, 2024, the Company incurred a net loss of \$15.6 million and used \$11.7 million cash in operating activities. Net cash used in operating activities for the period ended September 30, 2024 decreased by \$2.2 million from \$13.9 million for the period ended September 30, 2023. A The losses and the uses of cash are primarily due to the Company's administrative and product research and development activities. Administrative functions relate to costs to support the Company's public reporting and investor relations activities, readying for commercial development of its lead product candidate in the event of receiving PMA approval from the FDA, and internal administrative functions. Research and development activities are for continued product development and clinical trials for our product candidates, currently the VenoValve® and enVVe®. The Company will continue to incur these costs to complete its clinical trials, enhance products, develop new products, and operate as a public company. Although we have discretion in how we use the Company's cash resources, we expect to continue these activities for the foreseeable future as we seek to develop and obtain regulatory approval for our product candidates. We are not currently generating revenue and do not expect significant revenue until we successfully commercialize one or more of our product candidates. A Our cash flows from investing activity consist of maturities and purchases of US Treasury bills from our program to invest excess cash, and purchases of property and equipment for our lab and offices. During the nine months ended September 30, 2024 we purchased \$33.4 million of treasury bills and \$45.8 million of them matured generating \$1.4 million in realized gains and interest income. We expect to continue investing as the treasury bills mature and as allowed by the cash requirements of our operations. In the nine months ended September 30, 2024, our purchases of property and equipment consisting primarily of lab and test equipment, were less than \$0.1 million. A We do not currently have material commitments for capital expenditures or other expenditures except for our facility lease commitment of \$0.4 million per year. However, we expect a modest increase in purchases of property and equipment as we continue SAVVE, plan for commercialization of the VenoValve and continue development of enVVe. Our future capital requirements will remain dependent upon a variety of factors, especially including the success of our clinical trials and related product development costs and our ability to successfully bring products to market. A 14 A We have historically funded our operations through financing activities. On September 30, 2024, we closed an offering issuing stock and warrants and raising approximately \$13.6 million net cash proceeds. Based upon our cash and working capital as of September 30, 2024 we have sufficient capital resources to meet our obligations as they become due for at least one year after the date of this Report and sustain operations, although we expect to continue incurring losses for the foreseeable future and may need to raise additional capital to sustain our operations, pursue our product development initiatives and penetrate markets for the sale of our products. Any inability to raise additional financing in the foreseeable future would have a material adverse effect on us. A As of October 28, 2024, we had cash and investments of \$47.1 million. A Off-Balance Sheet Arrangements A None A Contractual Obligations A As a smaller reporting company, we are not required to provide the information requested by paragraph (a)(5) of this Item. A Critical Accounting Policies and Estimates For a description of our critical accounting policies, see Note 3 "Significant Accounting Policies in Part 1, Item 1 of this Quarterly Report on Form 10-Q. A Item 3. Quantitative and Qualitative Disclosure About Market Risk A As a "smaller reporting company" as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. A Item 4: Controls and Procedures A Disclosure Controls and Procedures Our management carried out an evaluation, under the supervision and with the participation of our Chief Executive Officer (who is our Principal Executive Officer) and our Chief Financial Officer (who is our Principal Financial Officer and Principal Accounting Officer), of the effectiveness of the design of our disclosure controls and procedures (as defined by Exchange Act Rules 13a-15(e) or 15d-15(e)) as of September 30, 2024, pursuant to Exchange Act Rule 13a-15(b). Based upon that evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2024. A Changes in Internal Control over Financial Reporting A During the nine months ended September 30, 2024, there were no changes in our internal controls over financial reporting, or in other factors that could significantly affect these controls, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. A Inherent Limitations of Controls Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. Controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within the Company

have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

15 A PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time we may be subject to litigation and arbitration claims incidental to its business. Such claims may not be covered by our insurance coverage, and even if they are, if claims against us are successful, they may exceed the limits of applicable insurance coverage.

The Company was party to litigation with former employee, Robert Rankin, who resigned on March 30, 2020. The matter was resolved on October 21, 2024 and all complaints and cross complaints were dismissed with prejudice.

Item 1A. Risk Factors

As a smaller reporting company as defined by Item 10 of Regulation S-K, we are not required to provide information required by this Item. Our current risk factors are set forth in our Form 10-K, filed with the SEC on February 29, 2024.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine and Safety Disclosure

Not applicable.

Item 5. Other Information

Trading Arrangements

On September 19, 2024, Marc Glickman, our Chief Medical Officer, entered into a pre-arranged trading plan (the "10b5-1 plan") that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. Under the 10b5-1 plan, Mr. Glickman can sell up to 653,526 shares of our common stock between December 19, 2024 and December 31, 2025, subject to price and trading limitations under the plan.

16 A Item 6. Exhibits

The following is a complete list of exhibits filed as part of this Form 10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601 of Regulation S-K.

Exhibit A Description

A 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act.

* 31.2 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act

* 101.INS Inline XBRL Instance Document

* 101.SCH Inline XBRL Taxonomy Extension Schema Document

* 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document

* 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document

* 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document

* 101.PRE A Inline XBRL Taxonomy Extension Presentation Linkbase Document

* 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

A * Filed herewith.

** These certifications are furnished to the SEC pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

17 A SIGNATURES

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: October 30, 2024

ENVVENO MEDICAL CORPORATION

By: /s/ Robert Berman

Robert Berman

Chief Executive Officer

(Principal Executive Officer)

By: /s/ Craig Glynn

Craig Glynn

Chief Financial Officer

(Principal Financial and Accounting Officer)

18 EX-31.1 2 ex31-1.htm

Exhibit 31.1 CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Robert Berman, certify that:

A 1. I have reviewed this Quarterly Report on Form 10-Q of enVveno Medical Corporation;

A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

A 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 30, 2024

/s/ Robert Berman

Name: Robert Berman

Title: Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 ex31-2.htm

Exhibit 31.2 CERTIFICATION PURSUANT TO RULE 13a-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934

I, Craig Glynn, certify that:

A 1. I have reviewed this Quarterly Report on Form 10-Q of enVveno Medical Corporation;

A 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

A 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

A 4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

October 30, 2024

/s/ Craig Glynn

Name: Craig Glynn

Title: Chief Financial Officer

(Principal Financial Officer)

EX-32 4 ex32.htm

Exhibit 32 CERTIFICATION PURSUANT TO 18 U.S.C. Â§1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of enVveno Medical Corporation (the "Company") on Form 10-Q for the period ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Robert Berman, as Chief Executive Officer and principal executive officer and Craig Glynn, as Chief Financial Officer and principal financial officer of the Company hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of the undersigned's knowledge and belief, that:

A 1. The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

A 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report.

/s/ Robert Berman

Robert Berman

Chief Executive Officer and Principal Executive Officer

Dated: October 30, 2024

/s/ Craig Glynn

Craig Glynn

Chief Financial Officer and Principal Financial Officer

Dated: October 30, 2024

This certification accompanies this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.

EX-101.SCH 5 nvno-20240930.xsd

XBRL SCHEMA FILE

00000001 - Document - Cover

link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Balance Sheets (Unaudited)

link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)

link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Statements of Operations (Unaudited)

link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)

link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Statements of Cash Flows (Unaudited)

link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Business Organization and Nature of Operations

link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Management's Liquidity Plan

link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Significant Accounting Policies

link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Investments

link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Concentrations

link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities

link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Commitments and Contingencies

link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Stockholders' Equity

link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Net Loss per Share

link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Significant Accounting Policies (Policies)

link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Investments (Tables)

link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables)

link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Stockholders' Equity (Tables)

link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Net Loss per Share (Tables)

link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Management's Liquidity Plan (Details Narrative)

link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Schedule of Components of Investments (Details)

link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Concentrations (Details Narrative)

link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities (Details)

link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Schedule of Estimated Fair values and Assumptions (Details)

link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Stockholders' Equity (Details Narrative)

link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details)

link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 nvno-20240930_cal.xml

XBRL CALCULATION FILE

EX-101.DEF 7 nvno-20240930_def.xml

XBRL DEFINITION FILE

EX-101.LAB 8 nvno-20240930_lab.xml

XBRL LABEL FILE

Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Fair Value Hierarchy and NAV [Axis] Fair Value, Inputs, Level 1 [Member] Investment Type [Axis] US Government Debt Securities [Member] Asset Class [Axis] Debt Securities [Member] Class of Warrant or Right [Axis] Pre-Funded Warrants [Member] Underwriter [Member] Warrant [Member] Statement of Income Location, Balance [Axis] Selling, General and Administrative Expenses [Member] Antidilutive Securities [Axis] Share-Based Payment Arrangement, Option [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State

or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current Assets: Cash and cash equivalents Short-term investments Prepaid expenses and other current assets Total current assets Property and equipment, net Operating lease right-of-use assets, net Security deposits and other assets Total assets Liabilities and Stockholdersâ€™ Equity Current Liabilities: Accounts payable, accrued expenses and other current liabilities Current portion of operating lease liabilities Total current liabilities Long-term operating lease liabilities Total liabilities Commitments and Contingencies Stockholdersâ€™ Equity: Preferred stock, par value \$0.00001, 10,000 shares authorized: no shares issued or outstanding Common stock, par value \$0.00001, 250,000 shares authorized, 17,536 and 13,317 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid-in capital Accumulated deficit Total stockholdersâ€™ equity Total liabilities and stockholdersâ€™ equity Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating Expenses: Research and development expenses Selling, general and administrative expenses Loss from Operations Other Income: Realized gain from sales of trading securities Unrealized gain from trading securities Interest income, net Total Other Income Net Loss Net Loss Per Basic Common Share Net Loss Per Diluted Common Share Weighted Average Number of Common Shares Outstanding: Basic Diluted Statement [Table] Statement [Line Items] Balance Balance, shares Common Stock and Warrants Issued in Public Offering Common Stock and Warrants Issued in Public Offering, shares Share-Based Compensation Net loss Options exercised Options exercised, shares Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Share-based compensation Depreciation and amortization Amortization of right-of-use assets Unrealized gain from investments, net Changes in operating assets and liabilities: Prepaid expenses and other current assets Security deposit and other assets Accounts payable, accrued expenses and other current liabilities Operating lease liabilities Net Cash Used in Operating Activities Cash Flows from Investing Activities Purchase of property and equipment Purchases of investments Maturities of investments Net Cash Provided by Investing Activities Cash Flows from Financing Activities Proceeds from public offering Proceeds from stock option exercises Net Cash Provided by Financing Activities Net Increase in Cash, Cash Equivalents Cash, cash equivalents - Beginning of period Cash, cash equivalents - End of period Organization, Consolidation and Presentation of Financial Statements [Abstract] Business Organization and Nature of Operations Managementâ€™s Liquidity Plan Accounting Policies [Abstract] Significant Accounting Policies Cash and Cash Equivalents [Abstract] Investments Risks and Uncertainties [Abstract] Concentrations Payables and Accruals [Abstract] Accounts Payable, Accrued Expenses and Other Current Liabilities Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Equity [Abstract] Stockholdersâ€™ Equity Earnings Per Share [Abstract] Net Loss per Share Basis of Presentation Schedule of Components of Investments Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities Schedule of Estimated Fair values and Assumptions Schedule of Dilutive Net Loss Per Common Share Cash Investments Working capital Platform Operator, Crypto Asset [Table] Platform Operator, Crypto Asset [Line Items] Cash equivalents Short-term investments FDIC amount Uninsured cash balances Accounts payable Accrued compensation costs Other accrued expenses Total accrued expenses and other current liabilities Contractual term in years Volatility Risk free interest rate Dividend yield Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Line Items] Proceeds from issuance of common stock Number of shares issued Number of warrant shares Warrant exercise price Payments of stock issuance costs Warrants and rights outstanding Stock-based compensation Unrecognized stock-based compensation expense Weighted average remaining vesting period Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Potentially dilutive common stock equivalents excluded from diluted net loss per share Security deposits and other assets noncurrent. Working capital. Pre-Funded Warrants [Member] Underwriter [Member] Assets, Current Assets [Default Label] Liabilities, Current Liabilities Equity, Attributable to Parent Liabilities and Equity Operating Income (Loss) Nonoperating Income (Expense) Shares, Outstanding Unrealized Gain (Loss) on Investments Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Deposit Assets Increase (Decrease) in Accounts Payable and Accrued Liabilities Net Cash Provided by (Used in) Operating Activities Payments to Acquire Property, Plant, and Equipment Payments to Acquire Investments Net Cash Provided by (Used in) Investing Activities Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Commitments and Contingencies Disclosure [Text Block] Investments [Default Label] Investments, Fair Value Disclosure Accrued Liabilities and Other Liabilities EX-101.PRE 9 nvno-20240930_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Oct. 28, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Amendment Flag false Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Period Focus Q3 Â Document Fiscal Year Focus 2024 Â Current Fiscal Year End Date --12-31 Â Entity File Number 001-38325 Â Entity Registrant Name enVveno Medical Corporation Â Entity Central Index Key 0001661053 Â Entity Tax Identification Number 33-0936180 Â Entity Incorporation, State or Country Code DE Â Entity Address, Address Line One 70 Doppler Â Entity Address, City or Town Irvine Â Entity Address, State or Province CA Â Entity Address, Postal Zip Code 92618 Â City Area Code (949) Â Local Phone Number 261-2900 Â Title of 12(b) Security Common Stock, \$0.00001 par value Â Trading Symbol NVNO Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Non-accelerated Filer Â Entity Small Business true Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 17,536,000 X - Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. + References No definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Area code of city + References No definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Cover page. + References No definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Definition End date of current fiscal year in the format --MM-DD. + References No definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + References No definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + References No definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - Definition For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + References No definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateTimeItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as an quarterly report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true only for a form used as a transition report. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + References No definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - Definition Address Line 1 such as Attn, Building Name, Street Name + References No definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the City or Town + References No definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Code for the postal or zip code + References No definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Name of the state or province. + References No definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceCodeItemType Balance Type: na Period Type: duration X - Definition A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - Definition Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + References No definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Definition Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References No definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition Indicate if registrant meets the emerging growth company criteria. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + References No definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - Definition Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - Definition Two-character EDGAR code representing the state or country of incorporation. + References No definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryCodeItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - Definition The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - Definition Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + References Reference 1: <http://www.xbrl.org/2003/role/presentationRef> - Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - Definition Indicates that the company is a Smaller Reporting Company

(SRC). + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntitySmallBusiness Namespace Prefix: dei Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei EntityTaxIdentificationNumber Namespace Prefix: dei Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei LocalPhoneNumber Namespace Prefix: dei Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei Security12bTitle Namespace Prefix: dei Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef> -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei SecurityExchangeName Namespace Prefix: dei Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei TradingSymbol Namespace Prefix: dei Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Balance Sheets (Unaudited) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current Assets: Á Á Cash and cash equivalents \$ 17,915 \$ 3,620 Short-term investments 30,464 42,792 Prepaid expenses and other current assets 672 511 Total current assets 49,051 46,923 Property and equipment, net 218 334 Operating lease right-of-use assets, net 1,092 1,347 Security deposits and other assets 31 31 Total assets 50,390 48,635 Current Liabilities: Á Á Accounts payable, accrued expenses and other current liabilities 1,872 1,033 Current portion of operating lease liabilities 357 338 Total current liabilities 2,229 1,371 Long-term operating lease liabilities 791 1,064 Total liabilities 3,020 2,435 Commitments and Contingencies Stockholdersâ€™ Equity: Á Á Preferred stock, par value \$0.00001, 10,000 shares authorized; no shares issued or outstanding Common stock, par value \$0.00001, 250,000 shares authorized, 17,536 and 13,317 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively Additional paid-in capital 192,996 176,236 Accumulated deficit (145,626) (130,036) Total stockholdersâ€™ equity 47,370 46,200 Total liabilities and stockholdersâ€™ equity \$ 50,390 \$ 48,635 X - DefinitionSecurity deposits and other assets noncurrent. + ReferencesNo definition available. + Details Name: NVNO SecurityDepositsAndOtherAssetsNoncurrent Namespace Prefix: NVNO Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AccountsPayableAndAccruedLiabilitiesCurrent Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap AdditionalPaidInCapital Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482964/270-10-50-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 5: <http://fasb.org/us-gaap/role/ref/otherTransitionRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-32>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 12: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 13: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 19: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 23: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 28: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481404/852-10-50-7>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482810/280-10-50-30>Reference 30: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1> + Details Name: us-gaap Assets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 6: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 10: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 11: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16: <https://asc.fasb.org/1943274/2147480097/470-10-S99-1>Reference 16:

1Reference 6:

0.00001 \$ 0.00001 Preferred stock, shares authorized 10,000 10,000 Preferred stock, shares issued 0 0 Preferred stock, shares outstanding 0 0 Common stock, par value \$ 0.00001 \$ 0.00001 Common stock, shares authorized 250,000 250,000 Common stock, shares issued 17,536 13,317 Common stock, shares outstanding 17,536 13,317 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1:

gaap RealizedInvestmentGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writteoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16+Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <a href=)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10+Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Changes in Stockholders' Equity (Unaudited) - USD ($) shares in Thousands, $ in Thousands Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] Total Balance at Dec. 31, 2022 $ 145,249 $ (106,520) $ 38,729 Balance, shares at Dec. 31, 2022 9,472 Á Á Share-Based Compensation 4,053 4,053 Net loss (17,867) (17,867) Balance at Sep. 30, 2023 149,302 (124,387) 24,915 Balance, shares at Sep. 30, 2023 9,472 Á Á Balance at Jun. 30, 2023 148,198 (119,386) 28,812 Balance, shares at Jun. 30, 2023 9,472 Á Á Share-Based Compensation 1,104 1,104 Net loss (5,001) (5,001) Balance at Sep. 30, 2023 149,302 (124,387) 24,915 Balance, shares at Sep. 30, 2023 9,472 Á Á Balance at Dec. 31, 2023 176,236 (130,036) 46,200 Balance, shares at Dec. 31, 2023 13,317 Á Á Common Stock and Warrants Issued in Public Offering 13,591 13,591 Common Stock and Warrants Issued in Public Offering, shares 4,206 Á Á Share-Based Compensation 3,123 3,123 Net loss (15,590) (15,590) Options exercised 46 46 Options exercised, shares 13 Á Á Balance at Sep. 30, 2024 192,996 (145,626) 47,370 Balance, shares at Sep. 30, 2024 17,536 Á Á Balance at Jun. 30, 2024 178,402 (139,984) 38,418 Balance, shares at Jun. 30, 2024 13,330 Á Á Common Stock and Warrants Issued in Public Offering 13,591 13,591 Common Stock and Warrants Issued in Public Offering, shares 4,206 Á Á Share-Based Compensation 1,003 1,003 Net loss (5,642) (5,642) Balance at Sep. 30, 2024 $ 192,996 $ (145,626) $ 47,370 Balance, shares at Sep. 30, 2024 17,536 Á Á X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: <a href=)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12+Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <a href=)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-16+Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: <a href=)Reference 2:

instant X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-03\(i\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_ StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(c\)\(1\)\(iv\)\(02\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_ StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(28\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3) + Details Name: us-gaap_ StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1) + Details Name: us-gaap_ StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(29\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(30\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(31\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: <http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 5: <http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.6-04\(19\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SX 210.6-05\(4\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(4\)\(b\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(6\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph \(SX 210.6-09\(7\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 12: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph \(SAB 2014.4.E\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB 2014.4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2) + Details Name: us-gaap_ StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Statements of Cash Flows (Unaudited) - USD (\$) in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash Flows from Operating Activities Á Á Net loss \$ (15,590) \$ (17,867) Adjustments to reconcile net loss to net cash used in operating activities: Á Á Share-based compensation 3,123 4,052 Depreciation and amortization 149 165 Amortization of right-of-use assets 257 247 Unrealized gain from investments, net (96) (567) Changes in operating assets and liabilities: Á Á Prepaid expenses and other current assets (118) (155) Security deposit and other assets (43) (8) Accounts payable, accrued expenses and other current liabilities 839 484 Operating lease liabilities (254) (236) Net Cash Used in Operating Activities (11,733) (13,885) Cash Flows from Investing Activities Á Á Purchase of property and equipment (33) (29) Purchases of investments (33,420) (24,276) Maturities of investments 45,844 38,581 Net Cash Provided by Investing Activities 12,391 14,276 Cash Flows from Financing Activities Á Á Proceeds from public offering 13,591 Proceeds from stock option exercises 46 Net Cash Provided by Financing Activities 13,637 Net Increase in Cash, Cash Equivalents 14,295 391 Cash, cash equivalents - Beginning of period 3,620 4,555 Cash, cash equivalents - End of period \$ 17,915 \$ 4,946 X - ReferencesNo definition available. + Details Name: us-gaap_ AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4> + Details Name: us-gaap_ CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1) + Details Name: us-gaap_ DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid. + ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(a\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28) + Details Name: us-gaap_ IncreaseDecreaseInAccountsPayableAndAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration

X - DefinitionThe increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInDepositOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478964/842-20-50-4> + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24> + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-25> + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 13: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 15: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 20: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1>Reference 21: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 22: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 23: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 24: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 25: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 26: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 27: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 28: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 29: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 33: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 37: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478524/942-220-S99-1> + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-28> + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow associated with the purchase of all investments (debt, security, other) during the period. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquireInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-13> + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-14> + Details Name: us-

us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period. + ReferencesReference 1:

<https://asc.fasb.org/1943274/2147482648/440-10-50-3>Reference 6: [https://asc.fasb.org/1943274/2147482648/440-10-50-3](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440 - Name Accounting Standards Codification - Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract])Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440 - Name Accounting Standards Codification - Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Equity \[Abstract\]](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440 - Name Accounting Standards Codification - Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity 9 Months Ended Sep. 30, 2024 Equity [Abstract]) <https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(d\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2)Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.3-04\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(e\) \(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e) (1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent>Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(g\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph \(i\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18)Reference 19:

earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482662/260-10-50-1> + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItem Type Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Managementâ€™s Liquidity Plan (Details Narrative) \$ in Millions Sep. 30, 2024 USD (\$) Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Cash \$ 48.4 Investments 48.4 Working capital \$ 47.3 X - DefinitionWorking capital. + ReferencesNo definition available. + Details Name: NVNO_WorkingCapital Namespace Prefix: NVNO_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a) (2)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477796/946-210-45-21>Reference 6: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef> -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477796/946-210-45-20> + Details Name: us-gaap_Cash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all investments. + ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef> -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480078/944-80-55-14>Reference 2: <http://www.xbrl.org/2003/role/exampleRef> -Topic 944 -SubTopic 80 -Name Accounting Standards Codification -Section 55 -Paragraph 9 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480078/944-80-55-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(h)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)(6)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> + Details Name: us-gaap_Investments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Components of Investments (Details) - Fair Value, Inputs, Level 1 [Member] - Debt Securities [Member] - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Platform Operator, Crypto Asset [Line Items] Â Cash equivalents \$ 3,794 \$ 3,187 Short-term investments \$ 30,464 \$ 42,792 US Government Debt Securities [Member] Â Platform Operator, Crypto Asset [Line Items] Â Cash equivalents \$ 3,794 \$ 3,187 Short-term investments \$ 30,464 \$ 42,792 X - ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 405 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.5F.Q2) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147476188/405-10-S99-1> + Details Name: srt_PlatformOperatorCryptoAssetLineItems Namespace Prefix: srt_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionFair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method. + ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 3: <http://www.xbrl.org/2009/role/commonPracticeRef> -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2> + Details Name: us-gaap_InvestmentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_USGovernmentDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Concentrations (Details Narrative) - USD (\$) \$ Sep. 30, 2024 Dec. 31, 2023 Risks and Uncertainties [Abstract] Â FDIC amount \$ 250,000 Â Uninsured cash balances \$ 14,900,000 \$ 3,400,000 X - DefinitionThe amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap_CashFDICInsuredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - DefinitionThe amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation. + ReferencesNo definition available. + Details Name: us-gaap_CashUninsuredAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertaintiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) - USD (\$) \$ in Thousands Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Accounts payable \$ 894 \$ 427 Accrued compensation costs 446 478 Other accrued expenses 532 128 Total accrued expenses and other current liabilities \$ 1,872 \$ 1,033 X - DefinitionAmount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_AccountsPayableOtherCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AccruedLiabilitiesAndOtherLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef> -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> + Details Name: us-gaap_WorkersCompensationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItem Type Balance Type: credit Period Type: instant XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Estimated Fair values and Assumptions (Details) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Contractual term in years 5 years Volatility 102.00% Risk free interest rate 4.00% Dividend yield 0.00% X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItem Type Balance Type: na Period Type: duration X - DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef> -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2> + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItem Type Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholdersâ€™ Equity (Details Narrative) - USD (\$) \$ / shares in Units, shares in Thousands, \$ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Proceeds from issuance of common stock Â Â \$ 13,300 Â Payments of stock issuance costs Â Â 1,400 Â Warrants and rights outstanding \$ 1,000 Â 1,000 Â Stock-based compensation Â Â 3,123 \$ 4,052 Unrecognized stock-based compensation expense 4,300 Â \$ 4,300 Â Weighted average remaining vesting period Â Â 1 year 10 months 24 days Â Selling, General and Administrative Expenses [Member] Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Stock-based compensation \$ 1,000 \$ 1,100 \$ 3,100 \$ 4,100 Pre-Funded Warrants [Member] Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Number of warrant shares 100 Â 100 Â Underwriter [Member] Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Number of warrant shares 300 Â 300 Â Common Stock [Member] Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Number of shares issued 4,206 Â 4,206 Â Warrant [Member] Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Warrant exercise price \$ 3.18 Â \$ 3.18 Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information

associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap AccumulatedOtherComprehensiveIncomeLossItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instant X - DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details Name: us-gaap ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/214748448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionValue of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap WarrantsAndRightsOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=NVNO_PrefundedWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap ClassOfWarrantOrRightAxis=NVNO_UnderwriterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap StatementEquityComponentsAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Dilutive Net Loss Per Common Share (Details) - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Å Å Potentially dilutive common stock equivalents excluded from diluted net loss per share 15,399 8,760 Warrant [Member] Å Å Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Å Å Potentially dilutive common stock equivalents excluded from diluted net loss per share 9,847 4,506 Share-Based Payment Arrangement, Option [Member] Å Å Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Å Å Potentially dilutive common stock equivalents excluded from diluted net loss per share 5,552 4,254 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItem Type Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: XCEL 38 Financial Report.xlsx IDEA: XBRL DOCUMENT being 644 Financial Report.xlsx M4\$!L#10 ((^:TED'04UB@0 + \$ 0 9&[C4']<0&7P!+GAM M;,\$V'/0L',11\$ /EQO=;=P4)B0-12L+(/>QLOD&1#LD)~OCGICVX>;QA&WPIG M*N*~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d6L XCU'ODRWSEPVSK> UIF M\$RQ#I!?!? 8J)*@&K8KZZKT_Y9PJ[M]QO@2".-;:/=[X Q'U'M:160K\$31+ M1WPD?9CC0%OT->8%&MIK&MQMHQ*F 6'J.,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_VJ0-J/8--R115XQF;8VH^1" C9C<_N1.L+&SCNMBL[X]#1!0 (+ M (^7EE GSBJP@4 +>8 >>P=VJR-W-H965T&UL MM9E;JLV%,7? ^RD(;QA6(XERG;B+C'@*.D6K\$W2,.00#7N@)=H6*HD:2=G) MMJ^E9\$M10%U[0MV'1O_7^Z%>DDGJV% *J6G&ORG,2I.N\LMBI3'(6%J[D]E"&? 82%J6=15EQ(J.Z.ST2N3ZCR@JY*H M\$F87+G@L5B?>J.SJL!M%&G! AYZ2-4#K%F MAM,!= -%+##*Z-JW 8<&WIX>7JZE?6) ME->8? 8AN&W14&.ISXZ2YQP1ZM^~ M13T^+K+]&@&AISY-WQJOOOC7%>>G_ GLR4AM#E K;H="A;WU7L'W,7?PI@AP>44T>7S(JN(7EKMJ/ M;."#52V1!A72 &W3!C"@NDZ9@L;ZZZ?LUC9;H6/REI^#2NHX7YU^!PSJ;F, M7@#SX34-C[<2LOJ6N*=5 @G>W9#R6~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

<RPO M=VJR:V>:VLN>&UL4\$!L A0#% @ CYI>67JWVVE' 0 V! I'H M C I'(W< 'AL+UJR96QS+W=O6=IR6=AX 0 L1\$ I, (I'HG@ %M#;VYT D96YT7U1Y<&5572YX;6Q02P4#& (P/L'0 2WH end XML 39 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show=
 {,Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR()};var
 e=a;while(e&&e.nodeName!= 'TABLE')e=e.nextSibling;if(!e.nodeName!= 'TABLE'){var ref=(window)?w.document:document).getElementById(r);if(ref)
 {e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)} } if(e.e.style.display='block';Show.LastAR=e};Show.hideAR=function()
 {Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!= 'DIV')e=e.nextSibling;if(!e.style){ }else if(!e.style.display){ }else {var
 d,p ,if(e.style.display=='none') {d='block';p=''};else {d='none';p='+'} e.style.display=d;if(a.textContent)
 {a.textContent+=p+a.textContent.substring(1)}else {a.innerHTML+=p+a.innerHTML.substring(1)}} } XML 40 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /*
 v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData { background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData
 a { display: block; text-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px
 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width:
 400px; } .report table.authRefData table { font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color:
 white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels
 */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th,void { background-color: transparent; color: #000000; font: bold 10pt
 Helvetica, Arial, sans-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } /* word-wrap: break-
 word; */ .report td.pl a,a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color:
 #ffc; } /* Header rows... */ .report tr.th { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even
 rows... */ .report .re .report .re { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro .report .ro { background-color:
 white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */
 .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .num { text-align: right; white-space: nowrap; } .report .num { padding-left: 2em; }

.report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */.report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 42 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3.html 56 130 1 false 12 0 false 4 false false R1.htm 000000001 - Document - Cover Sheet http://envvveno.com/role/Cover Cover Cover 1 false false R2.htm 000000002 - Statement - Condensed Balance Sheets (Unaudited) Sheet http://envvveno.com/role/BalanceSheets Condensed Balance Sheets (Unaudited) Statements 2 false false R3.htm 000000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical) Sheet http://envvveno.com/role/BalanceSheetsParenthetical Condensed Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 000000004 - Statement - Condensed Statements of Operations (Unaudited) Sheet http://envvveno.com/role/StatementsOfOperations Condensed Statements of Operations (Unaudited) Statements 4 false false R5.htm 000000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited) Sheet http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity Condensed Statements of Changes in Stockholders' Equity (Unaudited) Statements 5 false false R6.htm 000000006 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://envvveno.com/role/StatementsOfCashFlows Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000000007 - Disclosure - Business Organization and Nature of Operations Sheet http://envvveno.com/role/BusinessOrganizationAndNatureOfOperations Business Organization and Nature of Operations Notes 7 false false R8.htm 000000008 - Disclosure - Management???s Liquidity Plan Sheet http://envvveno.com/role/ManagementsLiquidityPlan Management???s Liquidity Plan Notes 8 false false R9.htm 000000009 - Disclosure - Significant Accounting Policies Sheet http://envvveno.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 9 false false R10.htm 000000010 - Disclosure - Investments Sheet http://envvveno.com/role/Investments Investments Notes 10 false false R11.htm 000000011 - Disclosure - Concentrations Sheet http://envvveno.com/role/Concentrations Concentrations Notes 11 false false R12.htm 000000012 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities Sheet http://envvveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities Accounts Payable, Accrued Expenses and Other Current Liabilities Notes 12 false false R13.htm 000000013 - Disclosure - Commitments and Contingencies Sheet http://envvveno.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 13 false false R14.htm 000000014 - Disclosure - Stockholders??? Equity Sheet http://envvveno.com/role/StockholdersEquity Stockholders??? Equity Notes 14 false false R15.htm 000000015 - Disclosure - Net Loss per Share Sheet http://envvveno.com/role/NetLossPerShare Net Loss per Share Notes 15 false false R16.htm 000000016 - Disclosure - Significant Accounting Policies (Policies) Sheet http://envvveno.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://envvveno.com/role/SignificantAccountingPolicies 16 false false R17.htm 000000017 - Disclosure - Investments (Tables) Sheet http://envvveno.com/role/InvestmentsTables Investments (Tables) Tables http://envvveno.com/role/Investments 17 false false R18.htm 000000018 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables) Sheet http://envvveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables) Tables http://envvveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities 18 false false R19.htm 000000019 - Disclosure - Stockholders??? Equity (Tables) Sheet http://envvveno.com/role/StockholdersEquityTables Stockholders??? Equity (Tables) Tables http://envvveno.com/role/StockholdersEquity 19 false false R20.htm 000000020 - Disclosure - Net Loss per Share (Tables) Sheet http://envvveno.com/role/NetLossPerShareTables Net Loss per Share (Tables) Tables http://envvveno.com/role/NetLossPerShare 20 false false R21.htm 000000021 - Disclosure - Management???s Liquidity Plan (Details Narrative) Sheet http://envvveno.com/role/ManagementsLiquidityPlanDetailsNarrative Management???s Liquidity Plan (Details Narrative) Details http://envvveno.com/role/ManagementsLiquidityPlan 21 false false R22.htm 000000022 - Disclosure - Schedule of Components of Investments (Details) Sheet http://envvveno.com/role/ScheduleOfComponentsOfInvestmentsDetails Schedule of Components of Investments (Details) Details 22 false false R23.htm 000000023 - Disclosure - Concentrations (Details Narrative) Sheet http://envvveno.com/role/ConcentrationsDetailsNarrative Concentrations (Details Narrative) Details http://envvveno.com/role/Concentrations 23 false false R24.htm 000000024 - Disclosure - Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) Sheet http://envvveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities (Details) Details 24 false false R25.htm 000000025 - Disclosure - Schedule of Estimated Fair Values and Assumptions (Details) Sheet http://envvveno.com/role/ScheduleOfEstimatedFairValuesAndAssumptionsDetails Schedule of Estimated Fair values and Assumptions (Details) Details 25 false false R26.htm 000000026 - Disclosure - Stockholders??? Equity (Details Narrative) Sheet http://envvveno.com/role/StockholdersEquityDetailsNarrative Stockholders??? Equity (Details Narrative) Details http://envvveno.com/role/StockholdersEquityTables 26 false false R27.htm 000000027 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details) Sheet http://envvveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails Schedule of Dilutive Net Loss Per Common Share (Details) Details 27 false false All Reports Book All Reports form10-q.htm nvno-20240930.xsd nvno-20240930 cal.nvno-20240930 def.nvno-20240930 lab.nvno-20240930 pre.xml http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 true true JSON 44 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form10-q.htm": { "nsprefix": "NVNO", "nsuri": "http://envvveno.com/20240930", "dts": { "inline": { "local": ["form10-q.htm"] }, "schema": { "local": ["nvno-20240930.xsd"] }, "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["nvno-20240930 cal.xml"] }, "definitionLink": { "local": ["nvno-20240930 def.xml"] }, "labelLink": { "local": ["nvno-20240930 lab.xml"] }, "presentationLink": { "local": ["nvno-20240930 pre.xml"] } } }, "keyStandard": 128, "keyCustom": 2, "axisStandard": 7, "axisCustom": 0, "memberStandard": 9, "memberCustom": 2, "hidden": { "total": 45, "http://fasb.org/us-gaap/2024": 41, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 56, "entityCount": 1, "segmentCount": 12, "elementCount": 218, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 297, "http://xbrl.sec.gov/dei/2024": 29 }, "report": { "R1": { "role": "http://envvveno.com/role/Cover", "longName": "000000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "span": "p", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "b", "span": "p", "body", "html" }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R2": { "role": "http://envvveno.com/role/BalanceSheets", "longName": "000000002 - Statement - Condensed Balance Sheets (Unaudited)", "shortName": "Condensed Balance Sheets (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R3": { "role": "http://envvveno.com/role/BalanceSheetsParenthetical", "longName": "000000003 - Statement - Condensed Balance Sheets (Unaudited) (Parenthetical)", "shortName": "Condensed Balance Sheets (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "USDPSHares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "span", "td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R4": { "role": "http://envvveno.com/role/StatementsOfOperations", "longName": "000000004 - Statement - Condensed Statements of Operations (Unaudited)", "shortName": "Condensed Statements of Operations (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "From2024-07-01to2024-09-30", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R5": { "role": "http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "longName": "000000005 - Statement - Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "shortName": "Condensed Statements of Changes in Stockholders' Equity (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "AsOf2022-12-31 us-gaap:AdditionalPaidInCapitalMember", "name": "us-gaap:StockholdersEquity", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R6": { "role": "http://envvveno.com/role/StatementsOfCashFlows", "longName": "000000006 - Statement - Condensed Statements of Cash Flows (Unaudited)", "shortName": "Condensed Statements of Cash Flows (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "statement", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:NetIncomeLoss", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["td", "tr", "table", "body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R7": { "role": "http://envvveno.com/role/BusinessOrganizationAndNatureOfOperations", "longName": "000000007 - Disclosure - Business Organization and Nature of Operations", "shortName": "Business Organization and Nature of Operations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R8": { "role": "http://envvveno.com/role/ManagementsLiquidityPlan", "longName": "000000008 - Disclosure - Managementu2019s Liquidity Plan", "shortName": "Managementu2019s Liquidity Plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R9": { "role": "http://envvveno.com/role/SignificantAccountingPolicies", "longName": "000000009 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "R10": { "role": "http://envvveno.com/role/Investments", "longName": "000000010 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "disclosure", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US",

```

    "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R11": { "role": "http://envveno.com/role/Concentrations", "longName": "00000011 - Disclosure - Concentrations", "shortName": "Concentrations", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ConcentrationRiskDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R12": { "role": "http://envveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities", "longName": "00000012 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities", "shortName": "Accounts Payable, Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R13": { "role": "http://envveno.com/role/CommitmentsAndContingencies", "longName": "00000013 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R14": { "role": "http://envveno.com/role/StockholdersEquity", "longName": "00000014 - Disclosure - Stockholders\u2019 Equity", "shortName": "Stockholders\u2019 Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R15": { "role": "http://envveno.com/role/NetLossPerShare", "longName": "00000015 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R16": { "role": "http://envveno.com/role/SignificantAccountingPolicies", "longName": "00000016 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "16", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R17": { "role": "http://envveno.com/role/InvestmentsTables", "longName": "00000017 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "17", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:InvestmentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R18": { "role": "http://envveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "00000018 - Disclosure - Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accounts Payable, Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "18", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R19": { "role": "http://envveno.com/role/StockholdersEquityTables", "longName": "00000019 - Disclosure - Stockholders\u2019 Equity (Tables)", "shortName": "Stockholders\u2019 Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "19", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R20": { "role": "http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative", "longName": "00000021 - Disclosure - Management\u2019s Liquidity Plan (Details Narrative)", "shortName": "Management\u2019s Liquidity Plan (Details Narrative)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "21", "firstAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-09-30", "name": "us-gaap:Cash", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "span", "span", "p", "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R22": { "role": "http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails", "longName": "00000022 - Disclosure - Schedule of Components of Investments (Details)", "shortName": "Schedule of Components of Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "22", "firstAnchor": { "contextRef": "AsOf2024-09-30 us-gaap:FairValueInputsLevel1Member us-gaap:DebtSecuritiesMember", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTableTextBlock", "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock", "body", "html" ], "reportCount": 1, "base
```

```

ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "USD", "xsiNil": "false", "lang": "null", "decimals": "-5", "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "R27": { "role": "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "longName": "00000027 - Disclosure - Schedule of Dilutive Net Loss Per Common Share (Details)", "shortName": "Schedule of Dilutive Net Loss Per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "27", "firstAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "From2024-01-01to2024-09-30", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Shares", "xsiNil": "false", "lang": "null", "decimals": "-3", "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ] }, "reportCount": 1, "baseRef": "form10-q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap:AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://envveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilities", "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Expenses and Other Current Liabilities", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [ "r156" ] }, "us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://envveno.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Accounts payable, accrued expenses and other current liabilities", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r20", "r21" ] }, "us-gaap:AccountsPayableOtherCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap:AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Accounts payable", "documentation": "Amount of obligations incurred classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r19" ] }, "us-gaap:AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "totalLabel": true } }, "presentation": [ "http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails", "lang": { "en-us": { "role": { "label": "Total accrued expenses and other current liabilities", "label": "Accrued Liabilities and Other Liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [ ] }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r67", "r68", "r198", "r199", "r200", "r201", "r202", "r203" ] }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://envveno.com/role/StockholdersEquityDetailsNarrative", "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r67", "r68", "r198", "r199", "r200", "r201", "r202", "r203" ] }, "us-gaap:AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://envveno.com/role/BalanceSheets", "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r29", "r333", "r408" ] }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://envveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r243", "r378", "r379", "r380", "r381", "r394", "r409" ] }, "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://envveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "lang": { "en-us": { "role": { "label": "Share-Based Compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r15", "r16", "r149" ] }, "us-gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://envveno.com/role/StatementsOfCashFlows", "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities." } } }, "auth_ref": [ ] }, "dei:AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://envveno.com/role/Cover", "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [ ] }, "dei:AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://envveno.com/role/Cover", "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [ ] }, "dei:AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://envveno.com/role/Cover", "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r361" ] }, "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "lang": { "en-us": { "role": { "label": "Potentially dilutive common stock equivalents excluded from diluted net loss per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r98" ] }, "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r11" ] }, "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ ] }, "us-gaap:AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r11" ] }, "us-gaap:Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://envveno.com/role/BalanceSheets", "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets [Default Label]", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r49", "r56", "
```

"CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [{ "http://envvveno.com/role/BalanceSheets": { "label": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } }], "auth_ref": ["r10", "r62", "r318"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "presentation": [{ "http://envvveno.com/role/ScheduleOfComponentsOfInvestmentsDetails": { "lang": { "en-us": { "role": { "label": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": ["r395", "r396"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [{ "http://envvveno.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents - Beginning of period", "periodEndLabel": "Cash, cash equivalents - End of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": ["r10", "r39", "r72"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://envvveno.com/role/StatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [{ "http://envvveno.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "totalLabel": "Net Increase in Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } } }, "auth_ref": ["r0", "r39"] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [{ "http://envvveno.com/role/ConcentrationsDetailsNarrative": { "en-us": { "role": { "label": "FDIC amount", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } } }, "auth_ref": [] }, "us-gaap_CashUninsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashUninsuredAmount", "crdr": "debit", "presentation": [{ "http://envvveno.com/role/ConcentrationsDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Uninsured cash balances", "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation." } } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [{ "http://envvveno.com/role/Cover": { "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [{ "http://envvveno.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } } }, "auth_ref": ["r14"] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [{ "http://envvveno.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [{ "http://envvveno.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Warrant exercise price", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } } }, "auth_ref": ["r141"] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [{ "http://envvveno.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Number of warrant shares", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } } }, "auth_ref": ["r141"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://envvveno.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } } }, "auth_ref": ["r25", "r50", "r219", "r258"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [{ "http://envvveno.com/role/CommitmentsAndContingencies": { "lang": { "en-us": { "role": { "verboseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } } }, "auth_ref": ["r45", "r116", "r117", "r316", "r389", "r390"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [{ "http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity": { "http://envvveno.com/role/StockholdersEquityDetailsNarrative": { "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } } }, "auth_ref": ["r336", "r337", "r338", "r340", "r341", "r342", "r343", "r378", "r379", "r381", "r394", "r407", "r409"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [{ "http://envvveno.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, par value", "documentation": "Face amount or stated value per share of common stock." } } } }, "auth_ref": ["r28"] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [{ "http://envvveno.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } } }, "auth_ref": ["r28", "r259"] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [{ "http://envvveno.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } } }, "auth_ref": ["r28"] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [{ "http://envvveno.com/role/BalanceSheetsParenthetical": { "lang": { "en-us": { "role": { "label": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } } }, "auth_ref": ["r5", "r28", "r259", "r278", "r409", "r410"] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://envvveno.com/role/BalanceSheets": { "lang": { "en-us": { "role": { "label": "Common stock, par value \$0.00001, 250,000 shares authorized, 17,536 and 13,317 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } } }, "auth_ref": ["r28", "r222", "r333"] }, "us-gaap_ConcentrationRiskDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskDisclosureTextBlock", "presentation": [{ "http://envvveno.com/role/Concentrations": { "lang": { "en-us": { "role": { "label": "Concentrations", "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date." } } } }, "auth_ref": ["r43"] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [{ "http://envvveno.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [{ "http://envvveno.com/role/Cover": { "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": [{ "http://envvveno.com/role/ScheduleOfComponentsOfInvestmentsDetails": { "lang": { "en-us": { "role": { "label": "Debt Securities [Member]", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } } }, "auth_ref": ["r12", "r338", "r411"] }, "us-gaap_DebtSecuritiesUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://envvveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [{ "http://envvveno.com/role/StatementsOfOperations": { "lang": { "en-us": { "role": { "label": "Unrealized gain from trading securities", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } } }, "auth_ref": ["r230", "r373", "r374"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": { "http://envvveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [{ "http://envvveno.com/role/StatementsOfCashFlows": { "lang": { "en-us": { "role": { "label": "Depreciation and amortization", "documentation": "The current

period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r3", "r13"] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be U.S. GAAP, International Financial Reporting Standards, or Other." } } }, "auth_ref": ["r360"] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": ["r358", "r360", "r361"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "yearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r359"] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": ["r347"] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": ["r360"] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": ["r360"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r362"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": ["r350"] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss Per Basic Common Share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r70", "r81", "r82", "r83", "r84", "r85", "r86", "r91", "r93", "r95", "r96", "r97", "r101", "r163", "r166", "r179", "r180", "r214", "r228", "r319"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss Per Diluted Common Share", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r70", "r81", "r82", "r83", "r84", "r85", "r86", "r93", "r95", "r96", "r97", "r101", "r163", "r166", "r179", "r180", "r214", "r228", "r319"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://envveno.com/role/NetLossPerShare"], "lang": { "en-us": { "role": { "label": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r90", "r98", "r99", "r100"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Weighted average remaining vesting period", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r155"] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Unrecognized stock-based compensation expense", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r393"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": ["r353"] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r349"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r349"] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": ["r366"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-

accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } } , "auth_ref": ["r349"] } , "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } } , "auth_ref": [] , "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } } , "auth_ref": ["r363"] } , "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } } , "auth_ref": ["r361"] } , "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } } , "auth_ref": [] } , "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } } , "auth_ref": ["r349"] } , "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } } , "auth_ref": ["r349"] } , "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } } , "auth_ref": ["r349"] } , "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } } , "auth_ref": ["r349"] } , "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } } , "auth_ref": [] } , "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } } , "auth_ref": ["r364"] } , "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } } , "auth_ref": [] } , "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://envveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "http://envveno.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } } , "auth_ref": ["r5", "r58", "r67", "r68", "r69", "r76", "r77", "r78", "r80", "r85", "r87", "r89", "r103", "r109", "r110", "r111", "r142", "r158", "r159", "r160", "r161", "r162", "r164", "r165", "r166", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r209", "r227", "r233", "r234", "r235", "r243", "r298"] } , "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": ["http://envveno.com/role/Cover"] , "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } } , "auth_ref": [] } , "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "documentation": "Class of asset." } } } , "auth_ref": ["r186", "r187", "r188", "r189", "r190", "r191", "r194", "r330"] } , "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } } , "auth_ref": ["r186", "r187", "r188", "r189", "r190", "r191", "r194", "r330"] } , "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } } , "auth_ref": ["r127", "r143", "r144", "r145", "r146", "r147", "r148", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r194", "r330"] } , "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } } , "auth_ref": ["r127", "r143", "r148", "r182", "r193", "r210", "r326", "r327", "r328", "r329"] } , "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } } , "auth_ref": ["r127", "r143", "r144", "r145", "r146", "r147", "r148", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r194", "r330"] } , "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } } , "auth_ref": [] } , "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } } , "auth_ref": ["r112", "r114", "r115", "r187", "r191", "r194", "r231", "r232", "r283", "r317", "r331", "r406"] } , "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"] , "lang": { "en-us": { "role": { "documentation": "Location in statement of income where disaggregated amount has been reported." } } } , "auth_ref": ["r114", "r115", "r187", "r191", "r194", "r231", "r232", "r283", "r317", "r331", "r406"] } , "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } } , "presentation": ["http://envveno.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "verboseLabel": "Accounts payable, accrued expenses and other current liabilities", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } } , "auth_ref": ["r2"] } , "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } } , "presentation": ["http://envveno.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "negatedLabel": "Security deposit and other assets", "label": "Increase (Decrease) in Deposit Assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } } , "auth_ref": ["r2"] } , "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://envveno.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities." } } } , "auth_ref": [] } , "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } } , "presentation": ["http://envveno.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "label": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } } , "auth_ref": ["r367", "r375"] } , "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } } , "presentation": ["http://envveno.com/role/StatementsOfCashFlows"] , "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } } , "auth_ref": ["r2"] } , "us-gaap_IncreaseDecreaseInInterestIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInterestIncomeOther", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } } , "presentation": ["http://envveno.com/role/StatementsOfOperations"] , "lang": { "en-us": { "role": { "label": "Interest income, net", "documentation": "Amount of interest income earned from interest bearing assets classified as other." } } } , "auth_ref": [] } , "us-gaap_InvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTableTextBlock", "presentation": ["http://envveno.com/role/InvestmentsTables"] , "lang": { "en-us": { "role": { "label": "Schedule of Components of Investments", "documentation": "Tabular disclosure of investment." } } } , "auth_ref": ["r368", "r369", "r387"] } , "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeAxis", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } } , "auth_ref": ["r246", "r247", "r248", "r249", "r250", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r338"] } , "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentTypeCategorizationMember", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "documentation": "Asset obtained to generate income or appreciate in value." } } } , "auth_ref": ["r246", "r247", "r248", "r249", "r250", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r338"] } , "us-gaap_Investments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Investments", "crdr": "debit", "presentation": ["http://envveno.com/role/ManagementsLiquidityPlanDetailsNarrative"] , "lang": { "en-us": { "role": { "verboseLabel": "Investments", "label": "Investments [Default Label]", "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments." } } } , "auth_ref": ["r216", "r217", "r334", "r335"] } , "us-gaap_InvestmentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsFairValueDisclosure", "crdr": "debit", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"] , "lang": { "en-us": { "role": { "verboseLabel": "Short-term investments", "label": "Investments, Fair Value Disclosure", "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method." } } } , "auth_ref": ["r395", "r396", "r400"] } , "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",

"presentation": ["http://envveno.com/role/Investments"], "lang": { "en-us": { "role": { "label": "Investments", "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment." } } }, "auth_ref": ["r196"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r7", "r20", "r21", "r22", "r23", "r24", "r25", "r26", "r75", "r108", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r168", "r169", "r170", "r197", "r257", "r320", "r346", "r391", "r402", "r403"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders' equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r33", "r51", "r224", "r333", "r377", "r388", "r401"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' equity 2019", "label": "Liabilities and Stockholders' equity 2019", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r22", "r61", "r75", "r108", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r168", "r169", "r170", "r197", "r333", "r391", "r402", "r403"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Current Liabilities", "label": "Current Liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Financing Activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r71"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flows from Financing Activities", "label": "Cash Flows from Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Provided by Investing Activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r71"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flows from Investing Activities", "label": "Cash Flows from Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap_OperatingExpensesAbstract", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Net Cash Used in Operating Activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r39", "r40", "r41"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities", "label": "Cash Flows from Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Net Loss", "label": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r34", "r41", "r54", "r59", "r65", "r66", "r69", "r75", "r79", "r81", "r82", "r83", "r84", "r85", "r88", "r89", "r94", "r108", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r163", "r166", "r180", "r197", "r226", "r280", "r296", "r297", "r344", "r391"] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "totalLabel": "Total Other Income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": ["r36"] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Other Income", "label": "Other Income", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Operating Expenses", "label": "Operating Expenses (Loss)", "documentation": "Operating expense for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": ["r55", "r321", "r382", "r383", "r384", "r385", "r386"] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": ["r207"] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-term operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": ["r207"] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Operating lease right-of-use assets, net", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": ["r206"] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Amortization of right-of-use assets", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": ["r376"] }, "us-gaap_OrganizationConsolidationAndPresentationOffinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffinancialStatementsAbstract", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": ["r17", "r48", "r238", "r239"] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Other accrued expenses", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r21"] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "Item 17 or Item 18 specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": ["r360"] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Payments of stock issuance costs", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": ["r9"] }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"],

"lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth ref": ["r37"] }, "us-gaap PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth ref": ["r38"] }, "srt PlatformOperatorCryptoAssetLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PlatformOperatorCryptoAssetLineItems", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto Asset [Line Items]" } } }, "auth ref": ["r113"] }, "srt PlatformOperatorCryptoAssetTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "PlatformOperatorCryptoAssetTable", "presentation": ["http://envveno.com/role/ScheduleOfComponentsOfInvestmentsDetails"], "lang": { "en-us": { "role": { "label": "Platform Operator, Crypto Asset [Table]" } } }, "auth ref": ["r113"] }, "dei PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth ref": ["r354"] }, "dei PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth ref": ["r356"] }, "NVNO PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://envveno.com/20240930", "localname": "PreFundedWarrantsMember", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants [Member]", "documentation": "Pre-Funded Warrants [Member]" } } }, "auth ref": [] }, "us-gaap PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://envveno.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth ref": ["r27", "r129"] }, "us-gaap PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://envveno.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth ref": ["r27", "r259"] }, "us-gaap PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": ["http://envveno.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth ref": ["r27", "r129"] }, "us-gaap PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://envveno.com/role/BalanceSheetsParenthetical"], "lang": { "en-us": { "role": { "label": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth ref": ["r27", "r259", "r278", "r409", "r410"] }, "us-gaap PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Preferred stock, par value \$0.00001, 10,000 shares authorized: no shares issued or outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth ref": ["r27", "r221", "r333"] }, "us-gaap PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth ref": ["r372"] }, "us-gaap ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from public offering", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth ref": ["r1"] }, "us-gaap ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": ["http://envveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth ref": ["r1"] }, "us-gaap ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Maturities of investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth ref": ["r8"] }, "us-gaap ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/StatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Proceeds from stock option exercises", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth ref": ["r1", "r6"] }, "us-gaap PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Property and equipment, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth ref": ["r4", "r208", "r215", "r225", "r333"] }, "us-gaap RealizedInvestmentGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": { "http://envveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Realized gain from sales of trading securities", "documentation": "Amount of realized gain (loss) on investment." } } }, "auth ref": ["r229"] }, "us-gaap ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://envveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://envveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Research and development expenses", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth ref": ["r157", "r317", "r322", "r404"] }, "us-gaap RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://envveno.com/role/BalanceSheets": { "parentTag": "us-gaap StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://envveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth ref": ["r30", "r47", "r223", "r236", "r237", "r242", "r260", "r333"] }, "us-gaap RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://envveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth ref": ["r58", "r76", "r77", "r78", "r80", "r85", "r87", "r89", "r109", "r110", "r111", "r158", "r159", "r160", "r161", "r162", "r164", "r165", "r166", "r171", "r173", "r174", "r176", "r178", "r204", "r205", "r233", "r235", "r243", "r409"] }, "us-gaap RisksAndUncertaintiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RisksAndUncertaintiesAbstract", "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]" } } }, "auth ref": [] }, "us-gaap ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": ["http://envveno.com/role/AccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable, Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth ref": [] }, "us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://envveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails"], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth ref": ["r11"] }, "us-gaap ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://envveno.com/role/NetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Dilutive Net Loss Per Common Share", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because of too so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth ref": ["r11"] }, "us-gaap ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://envveno.com/role/StockholdersEquityTables"], "lang": { "en-us": { "role": { "label": "Schedule of Estimated Fair values and Assumptions", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth ref": ["r395", "r396"] }, "dei Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://envveno.com/role/Cover"], "lang": { "en-

us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r348"] }, "dei Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": ["http://envvveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": ["r352"] } }, "NVNO_SecurityDepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://envvveno.com/20240930", "localname": "SecurityDepositsAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap Assets", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://envvveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Security deposits and other assets", "documentation": "Security deposits and other assets noncurrent." } } }, "auth_ref": [] }, "dei SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://envvveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r351"] } }, "dei SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": ["http://envvveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": ["r357"] }, "us-gaap SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://envvveno.com/role/StatementsOfOperations": { "parentTag": "us-gaap OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://envvveno.com/role/StatementsOfOperations"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative expenses", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r35"] }, "us-gaap SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://envvveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://envvveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envvveno.com/role/StatementsOfCashFlows", "http://envvveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Share-based compensation", "verboseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r2"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": ["http://envvveno.com/role/ScheduleOfEstimatedFairValuesAndAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": ["r153"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": ["http://envvveno.com/role/ScheduleOfEstimatedFairValuesAndAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": ["r152"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": ["http://envvveno.com/role/ScheduleOfEstimatedFairValuesAndAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Risk free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": ["r154"] }, "us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": ["http://envvveno.com/role/ScheduleOfEstimatedFairValuesAndAssumptionsDetails"], "lang": { "en-us": { "role": { "label": "Contractual term in years", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r151"] }, "us-gaap SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Shares, shares", "periodStartLabel": "Balance, shares", "periodEndLabel": "Balance, shares", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "us-gaap ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://envvveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-term investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": ["r52", "r53", "r371"] }, "us-gaap SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://envvveno.com/role/SignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r42", "r73"] }, "dei SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": ["http://envvveno.com/role/Cover"], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": ["r355"] }, "us-gaap StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "http://envvveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r5", "r28", "r31", "r32", "r58", "r67", "r68", "r69", "r76", "r77", "r78", "r80", "r85", "r87", "r89", "r103", "r109", "r110", "r111", "r142", "r158", "r159", "r160", "r161", "r162", "r164", "r165", "r166", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r209", "r227", "r233", "r234", "r235", "r243", "r298"] }, "us-gaap StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r76", "r77", "r78", "r103", "r205", "r213", "r240", "r245", "r251", "r252", "r253", "r254", "r255", "r256", "r259", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r339"] }, "us-gaap StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "auth_ref": [] }, "us-gaap StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": ["r76", "r77", "r78", "r103", "r107", "r205", "r213", "r240", "r245", "r251", "r252", "r253", "r254", "r255", "r256", "r259", "r262", "r263", "r264", "r265", "r266", "r268", "r269", "r270", "r271", "r273", "r274", "r275", "r276", "r277", "r279", "r281", "r282", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r298", "r339"] }, "us-gaap StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity", "http://envvveno.com/role/StockholdersEquityDetailsNarrative"], "lang": { "en-us": { "role": { "label": "Common Stock and Warrants Issued in Public Offering, shares", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": ["r5", "r27", "r28", "r47", "r241", "r298", "r314"] }, "us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Options exercised, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": ["r5", "r27", "r28", "r47", "r150"] }, "us-gaap StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Common Stock and Warrants Issued in Public Offering", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": ["r5", "r27", "r28", "r47", "r298", "r314", "r345"] }, "us-gaap StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": ["http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Options exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": ["r5", "r28", "r31", "r32", "r47"] }, "us-gaap StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://envvveno.com/role/BalanceSheets": { "parentTag": "us-gaap LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://envvveno.com/role/BalanceSheets", "http://envvveno.com/role/CondensedStatementsOfChangesInStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Total stockholders' equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r28", "r31", "r32", "r44", "r261", "r278", "r299", "r300", "r333", "r346", "r377", "r388", "r401", "r409"] }, "us-gaap StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://envvveno.com/role/BalanceSheets"], "lang": { "en-us": { "role": { "label": "Stockholders' equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r46", "r74", "r128", "r130", "r131", "r132", "r133", "r134", "r135", "r136", "r137", "r138", "r139", "r140", "r142", "r177", "r301", "r302", "r315"] }, "us-gaap SubstantialDoubtAboutGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "presentation": ["http://envvveno.com/role/ManagementsLiquidityPlan"], "lang": { "en-us": { "role": { "label": "Management's Liquidity Plan", "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations,

```

and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern." } } } }, "auth_ref": { "r18" } }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://envvveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [ ] }, "us-gaap_USGovernmentDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "USGovernmentDebtSecuritiesMember", "presentation": [ "http://envvveno.com/role/ScheduleOfComponentsOfInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "US Government Debt Securities [Member]", "documentation": "Debt securities issued by the United States government." } } }, "auth_ref": [ "r405" ] }, "NVNO_UnderwriterMember": { "xbrltype": "domainItemType", "nsuri": "http://envvveno.com/20240930", "localname": "UnderwriterMember", "presentation": [ "http://envvveno.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Underwriter [Member]", "documentation": "Underwriter [Member]" } } }, "auth_ref": [ ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://envvveno.com/role/StatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://envvveno.com/role/StatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Unrealized gain from investments, net", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r31" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://envvveno.com/role/ScheduleOfDilutiveNetLossPerCommonShareDetails", "http://envvveno.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r336", "r337", "r340", "r341", "r342", "r343" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://envvveno.com/role/StockholdersEquityDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Warrants and rights outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r397", "r398", "r399" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://envvveno.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r92", "r97" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://envvveno.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r91", "r97" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://envvveno.com/role/StatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares Outstanding" } } }, "auth_ref": [ ] }, "us-gaap_WorkersCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WorkersCompensationLiabilityCurrent", "crdr": "credit", "calculation": { "http://envvveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://envvveno.com/role/ScheduleOfAccountsPayableAccruedExpensesAndOtherCurrentLiabilitiesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued compensation costs", "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r21" ] }, "NVNO_WorkingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://envvveno.com/20240930", "localname": "WorkingCapital", "crdr": "credit", "presentation": [ "http://envvveno.com/role/ManagementsLiquidityPlanDetailsNarrative" ], "lang": { "en-us": { "role": { "label": "Working capital", "documentation": "Working capital." } } }, "auth_ref": [ ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://envvveno.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r365" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

https://asc.fasb.org/1943274/214748009/470-10-S99-1A ", "r393": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2 ", "r394": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1 ", "r395": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r396": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r397": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r398": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r399": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r400": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2 ", "r401": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28 ", "r402": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7 ", "r403": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7 ", "r404": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1 ", "r405": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477268/942-320-2 ", "r406": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3 ", "r407": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4 ", "r408": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1 ", "r409": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3 ", "r410": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3 ", "r411": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1 ", } ZIP 45 0001493152-24-043100-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-043100-xbrl.zip M4\$&L#1/0 ((?EDN\$VSMO@< &Y. * 97&S.TQ+&FAT;>V<-4 ; ; MRU;W?>YB+M'NOD&8*K+20C12ZL[W\$ AOQ| ^~^ W.IJ|^ | ^ J?9- 4GV<9/I0 JM>[ZC3] M-> >)5VOYY?K%3?LO=N?] =7Y;2^4B3ECIX>I89Z(O;-K&+>.C'E2<2?OF^C= M4;UV<5UQ3=<0[Y94WQ(*#AUM]J7H ^U4CR1ZO2[F6WU?2Z-J=OW]Q^~^U]&+&QW&WK?;SJL^?K?TZV>~1.-2>1JZBL>MO&NT K8ZW&=SAWK +?UH7GJ M>XIP(G;MS=75VVWQUKW ;>JPSQI?>MOMXOBKFS@6@1E2LT.2SEE? MJ@14U9=1Q%-<HK7JBSOZYQOZLR8TJCX/HZS,AT+WJZU+WW/Q9!..IJ4B M8=-[I8U4>21N3QJ]=WII WY'B'DD43UH4-XMTK\$W8I M5P8PJWR&3)/(GV'^1+ (&*PU)283INAS\$P6A=<= j#9E7FH1-Q06=I:H>5D M^-ZRWF(I)IBZXAL#0PSP\$W:R'\$S\$P0 JCE*;2J06&PB#3XI\$1-PG@R85EB M5 9,6VX@1GM&!)H&J!NI KD5@(JPWHC&540)*?+1, 9D/9:I0 M TT1? M IN GH43<(& UOV V ML@C;9R UI MP8/?G0;NRIT^MLFCM-4"2"-H=O1U(2[S]Q3L52+>;2'6 M1BU<3,9,02&/LZ?POOH8-XGV!QAE,I)/12-29QQRQJLI^~:H+HPE M^N+M*KOVMWG&?K25/OZKT^I577:XBEYG M#@C80FVSA=Z\$B-Z.W@;+&P+Q] M51QBRI,QB\$2:FYMZ2] IZJSOA:IX\$J0<=&{*IM9&}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jX?N3+JZQ.VK&6ENQ OSR<2J47T3>*D%).EG< @ 2J8G3+2X?7@C9+6& M D*GI/, ?D:O2MF-WZ5LZ64JV< 6 :!C'?Z 4 M !%7ZAZM?*OJUW+D'C0#&EK-S2;C^Q?>SSNS'I CWU] SV DOA:[LCG,M,FD\$&KJ]9/OGYBJ+[WESE7=G>J]UOU[KP2?>VUMVYUJ:M-N[M[D&R&J7YXNI MZGQ3@K/(W-K)KDKNJL7J2'9ON^<.(B,G PQ4Q[*LITXCWJ]3BO;[UJ6O M;F^IZOK8X?1YH#-I K@J;5O- F%;\$SW66E [O,O-LJ]T9OC:N42N@+KJF& MO%A3?8,4ZML2] [FZD>1J+1ZGCWMY:C[K5O;W9WJCYIVC 6H7CO

```

M:1#DZ=QC1,5^<< M338:E:,YG-S#->QNYFNM*CIJ/SO/ZH58J-Z.C.62PFT>S.F,EIVSNO:8E.M9
M"%%:.$? YP:PS/14/L)WJ$W6<17@>?%$KXY)P4&P90Q/&515531Y=PP[M]1(2$ _J]Q3Y EBI[,CT5] MJW=R=9/W>0PQ<0EF4-%&5)T6EKO*E-I0E*J)DO3(-W>W>
<1@?7(9C1BD):?2:5**J)MJO$S<14?>M4?4C:DI @SJTFQEB8+;KP+S3=1UCUHG61NL#&@<7EF,Q3YCTJZ DBW!&0SH?Q(V?P MJ?XUH31'=#-##+51B#&@
INQMF3J9UT44!-H#<KXJ0/>#B/L<1#<F407ZOK-NO($3"SIJR M=S&SNOZCL2*GF"EVUB6#=#<9<+T)Q?Y2AHP)V<^/UM;9,ZA$C&S*3$S$<:
M3Q3G6T1:"IQE0I4#)B(XM#15H^U20D9,YB0CIG?<XTVV@<J(X1DX6+9^OJ M(00EDEK 7 1C20&:R0*H%#-H#^1Q98H^12G+D-Y-GD7L*2*#DOW,0983B @B(> MIR^0IR?
FJCK TG2Y8G9GJ9/>0P0KLW+BI1!! 04-1^XU1(48Y1 IA2!M M R1LN5, #Q0#&7#52,5#46,50G^4G=52>K0I(CHH(PN1?>L>AG2^9JQ0P@/ MNINTR:~SS6(<~5F;8
8%;3EWN.%AZBIS G09=[XA=<#V0?REF1P M8A :<2+Q-.#A)1V90HG(<VSD: /L.Y#Q1E1385<2CCJ6#J(S(W/R,1)J>[NBA&S4;MG M-K?
X7UMFT(&1:WEGMD61E*JKLYJ),9JE8.HA?NRA< T/N?#H^<[K BIS M1>~K/LJ04L39T<P#E&+<+3QP-+ZJ.1?>:H. (?8L H$HVV A&$."7 M^~J8@?
_JT^CD27(L7L,N1,^, W>210>=>AJPX53.7=>9,7D&4WT-H#&)CCX MK=C'CXYP(S""5. MF.0 -O:P3XQ@1(I(XF KG#;VQ^S4E +[[IG> GL>PAIA*(QU4JU@H^0**
M2N02!,=(E'NEL12/JR<U&09 ECUD;2HC*J6ZD^<L18J)KUOY/I1AQ=4+M M<C;G .H%Y-1!PUOI&1A1U1BEFT>2AGX1J*(.&IORJ)1752<0Q0('4+LB1LMV%
M^0&@<3A)NBD(JR^800E1F4(E#<KE^Y 1#M;8$2K^TFLF4DB$H3>H^?IE=20> MJOY&2,I[&CJPG^? X^?H$<TAS#%08SN[K,KYD<C 7(24WJNO~W$Q(0S M-Q-I%K
J>_D:=#-!)7ZZ08B )G<^C'D<^<8&L 2?"RBLBNJ$ ^ _IQ+>H5**YNG>(N3%0 M2 P.K&L+<AV^7^<(.G^,2@/02GB (HHT$:T;S181JVLQWJ#&R^UA-
HA*VP1VO.KVNJY>?%G05J M?>?="B^NB^N2:8U^6303<4X<#%<W5^:AX=P5-X46@N 08ZF5U2JUVV(J MD 1
J]XRMS(BWP)7GUE3E1J1> /GVHRH9EC69M^Y*#<+<+7FWJ(QMHKK MKIS^EWM + C-8&LDCMNZD$[I1+OZ NK5?R** !J>^&KOS-V31AE[>@< 6 P M1#VGD"
(,)$Q00Y1P^%13="1<:D1Q.305 (Z1NA=P@0)11V+<ZMP^HO>1+<ZNJ?B8>=>=AZV1JCRGI969H+*=-21# M4N/K- ZQGYMQ8P5<1!S9^EJ=<7.YPO.FS=GC9^).H%6V#<+S"
(#BJJ0DU0. ML$STGXJX^?O^<?56N6<0#W419F2WLR$TO1Z5AB7H1@PCN$J?Q2,MRF* M(6506H1TAS92IH>XJUL ^Q1-W&T9K9Y-W&=-WX^DB?M^.&J/-
FA/J^<O/S0@ MLNA?>8(X#U&M60^L1 L7,XU1A,^QH(E/QTTT74CRL,X2F3 O,>J "Is". (JN^K+OSUX<# M66LQCB1812FD^KFD%>
EFN<C>S>:R>7^H6W=$L<YLUJOY=E^G1VCJ<N<+ M=<6S>>05NJ-N8UJKA$?>6JGX70>=>=>7J4WDT+L'D^9*0^J V J40R1M^9&)5* M_7<,7E4+1T0 QD9U/JAY$XB09Y?>
+<+E^J8, L+<7BG.R<9BQ=V&J, ^ M4^B1. 51%Q4#41K8$.02@<9%<8>J>G<7CT6D?7>4FC M^G1^L2+O C,8BPJ1-
%181)ZJF027TDX9&$>TIXREW^BS@Q1D$Y_ @>^B ) M^> 5HV1;4?10>4R$ Z3% DZ$OD04^D2^<5$KU^YIEE0%0$Z4LY;:E.IG=( M B1^T9D M^E@DS6;(1E76
W1;2^EYDA1J^U+<LENOZ7^1,1R8B,8^*P&R+BN4C$ M0T^E2,37$0&^<+>T1?>$1KQ1.1%#9*0M,(11/O2-@%2=0)G6^*V^FV1J?
MR2O089@<CJPT^F2(37$6&R48A@P=<#MJHL^0H6WGX8LL81$<SAO)9R2?D7SN M1X62G^50JCR,OPTC<00~0*0?<?<Y>=>OBDWYDQF8XD,@1DBB1R+8FT9SO>
M@3XCZ)8J[HP;E,UDLPPD^F2S+4DSDS8E,W^! SL$JM^*Y$@<J(ZF,I)@4IF< M7L1B1;IABU& /@NQ0S8IAGZH^HX1:55^O^L=+8B29D61&DGDHR323!<71^DIX+M1>))WVR4PD
MD^<4R20:PEDJORJ13?&J^R&K.GVTJ 92=ZB=1<^1Z$OTV9J^T B9T0 MOJ^RNT>:J=6T8M+<X$4^B1G1J1J7#&11/H^G?JYK$L@<OJ4TOPE,C0; M8(L1.^,3RW<
V>^*4=J1;D1H3<X0&J:YF58G8":. "TL JGA,(TG^<^>1%QZ MANTV>63$;EYTHV0T^?>S&3FGFV,Y7$2VP1?M5&S-GE^M5/O^#NNU4KG6^?I. M^ODJ$#*1.NF7
YSVUFJX85&;<=Q^<KVN2N.FT(9(61&7<5^Q G7ME@6 MCWJ/QDS0B5*^).G.2^1%NC-M%L,9R9^<6^"OV-VC1Z1 $M+>HM1N5NHT=IX6 M.HPO^CGQ+X1FGJ"?>
S<3^M9~*8ZNK1.^*/ WGJ(CIE+6Z.Y1+UJHSM,Y0^RZT,J%MSV?#ZN=10TP1(88FX,^<Z,4B91Z+WWA MBPL,0ZMV;:RW)A:NP3D10UW614>2IC BIQ!@S$R MOT+
(Q^?R Z0:~(6(604#1[BU?>J)X9TFQZAU1Y.1926J19>?>8^>#SHM M^<3 6JZXU(T+T=3XGV&^<7C>461^B^? 14.Z6+7#%SK3MZ^S^RJD^#RJ/G$ MK. O=F3C0QV^13?
40^C2,S,C&C+FBQ13&G:8^$5/UZSQ2?1V3_KV 55=M^PYN.Y1M^JLW^<21SSD)JF G5^K;G:RZ?G?S1>A1K1^7FZG;J)ETBJ1M^MD^MCR6% M^HO^<.8/L:~+^*S^E_-10/@4Z?
BN W59D(2^9HZ&=1P89E@M^TAD0;M0 [L=(6^41%RZ^BTJ6)8,[L=L2,1J=<?<K1.G$ M^:~*G; G0 Z^*C<UJG^"VHRF@V^21^Q9^KIR24^JL"
M0I^SC.4^0%<2BF5RU);H:M7>WLY6^RY=?<C^I^MPMOIT^2Q)T6PAEG&+IC^*US(E^?K^R7URYCK MK.+<7W0T1(2)$!^$ZX1W$CAZ17QO^>JHYZJ
4^0#<M4B2YJ^JYQVO^<^J< M^9J1**HW:B-G,1QV0UJNVPKYDF5V^<+3+B^<65$9PTD2^); VE?D1^<5 M+<9513@<VDVE^*M^JQI.Y5 T1<@3^K%PPDLK^123AL"
(*E0JR)D8(F,IG^T MI^H7J,^CNJAZ^KBW& EJ-G M@BFP;CPIB:T,4($ZD9Y914BUYO^U^P5W$ MA^HPBAN:~006?H^<4 H;7T3SPBETOJ3^11@E1A^Z1P$>44CIV&00EZ%<
MOU.^I^OS+XCEC,PX=IAG#HEXU(OKL& Z&?<X:50)2JBUJZ$43T^9;(>8< MCE( UT>CHP2F@. _R1B=S.O^HL=P&H^%)5XW^B(G)3 2%1X55FTJFN2R,Z
M3^L1T:M5>ZD861>XC>:"3T,7^7<5D^<+DGJAS6WNLU2 J4G(-74<8SL MQ$^*B>I@&8^P79#<=>=E^QR,Y^*T^U:7>=>0F<=<?>OR>U360#;V9U=5C34
M16HTW+J1^12^>M^R0)OX9P4E:5P^J[E+67&4JW-Q1^4HJ$;J6<=>Y< M^29PHQ9Q51!^N5C(2J/>XT;D6F;J1W&^XJ J)A@WRWF&F>IXLL+N&4^ M^ZL81^T=CR6-
+@<1+5^3IR^<0MDV&AS^XEA^<^F>P>S=E.8)QU9P(TRCS:A 8^9QK^05JK28^8H^1HJ^2BK^%NF2G,J^* MXO1K7.L>IG6L.A.O->?JYZ,8$(-C3H=HQ@=*A7W8H^QUM1JDE
F^JTTT MMQU:IE DHUB61JWF,%R N^QZ6A298^P^E8@M)M4^1-29JGGBJ_YJHN8 M>*<^<DKLL4^TF1^J,F8RE^D&P6
```

[illegible]

[illegible]

[illegible]

[illegible]

10pt">Unrealized and realized gains and losses on the accompanying statement of operations result from fixed income securities and are primarily attributable to changes in interest rates. Management does not believe any remaining unrealized losses represent impairments based on our evaluation of available evidence. </p></p><div data-bbox=

[illegible]

[illegible]